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ABSTRACT OF DISSERTATION

EFFECTS OF ADIPOCYTE DEFICIENCY OF ANGIOTENSIN TYPE 1A
RECEPTORS IN MODELS OF OBESITY AND HYPERCHOLESTEROLEMIA

Adipocytes express angiotensin II (AngII) receptors; however the direct
effects of AngII at the adipocyte remain unclear. Knockout mouse models of
renin-angiotensin system components exhibit reduced body weight, reduced
adiposity, improved glucose tolerance, and improved blood pressure when fed
high fat diets, which may be due to reduced action of AngII through the AT1aR in
adipocytes. Additionally, hypercholesterolemic AT1aR deficient mice are
protected from AngII-induced increases in atherosclerosis and abdominal aortic
aneurysm (AAA) formation. We hypothesized that deficiency of AT1aR in
adipocytes would reduce the development of obesity, obesity-induced disorders,
and vascular diseases. To test this hypothesis, we created a mouse model of
adipocyte AT1aR deficiency using the Cre/LoxP system. Adipocyte-AT1aR
deficiency confers no protection from the development of obesity or obesityassociated parameters. However, low fat fed adipocyte-AT1aR deficient mice
exhibit remarkable adipocyte hypertrophy and reductions in adipocyte
differentiation. These results demonstrate that AngII is a stimulus for adipocyte

differentiation and adipocyte hypertrophy alone is insufficient to initiate obesityassociated disorders. In hypercholesterolemic mice, adipocyte AT1aR deficiency
conferred no protection from diet or AngII-induced vascular diseases. Overall
these studies suggest the primary role of adipocyte AT1aRs is to promote
adipocyte differentiation and the development of small adipocytes.

Keywords: Angiotensin II, adipocytes, obesity, atherosclerosis, abdominal aortic
aneurysm
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SECTION I. BACKGROUND
1.1.1 The renin-angiotensin system (RAS)
The renin-angiotensin system (RAS) is an endocrine system that regulates
blood pressure through the actions of angiotensin peptides acting through
various angiotensin receptors. Angiotensin peptides are cleavage products of a
precursor protein, angiotensinogen (AGT). AGT is a glycosylated protein
secreted primarily from liver, though important secondary sources include
adipose and brain tissues. The aspartyl protease renin is produced in
juxtaglomerular cells and cleaves 10 amino acids from the N-terminus of AGT to
form the inactive peptide, angiotensin I (AngI). Subsequent cleavage of two
amino acids from the C-terminus of AngI by the metalloproteinase angiotensin
converting enzyme (ACE) produces the predominant peptide of this system,
angiotensin II (AngII) (Figures 1.1 and 1.2A). Catabolism of AngII by
aminopeptidases produces smaller angiotensin peptides such as angiotensin III
or IV and importantly, the C-terminal phenylalanine can be removed by
angiotensin converting enzyme 2 (ACE2) to form angiotensin-(1-7) (Ang(1-7)),
which acts through the Mas receptor to oppose the effects of AngII.
1.1.2 Angiotensin receptors
1.1.2.1 Types of angiotensin receptors and their tissue distributions
In humans, the actions of AngII are mediated by two G-protein coupled
receptors, angiotensin type 1 (AT1R) and angiotensin type 2 (AT2R) receptors.
Rodents, however, have two subtypes of the AT1R, the AT1aR and AT1bR,
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which are 94% homologous (Hein 1998). Prior to the identification of the rodent
subtypes, the human AT1R was found to share 95% homology with rat AT1R
(Bergsma 1992}. The AT1R in humans and the AT1aR in rodents are expressed
with similar tissue distributions, including kidney, adrenal gland, vasculature,
epicardium, liver, lung, circumventricular organs of the brain, ovaries/testes, and
adipose tissues (44, 70). In contrast, expression of AT1bR is limited to adrenal
gland, anterior pituitary gland, testes, hypothalamus, and resistance vessels (36,
52, 294). Knockout models provide another indication that the rodent AT1aR is
most similar to the AT1R of humans because AT1aR deficient mice demonstrate
reduced blood pressure in most studies, consistent with pharmacological
blockade of AT1R in humans, whereas AT1bR deficient mice do not demonstrate
this pathology (52, 119).

AT1bRs have been implicated in contractile

responses to AngII in mesenteric resistance vessels of mice, supporting tissuespecific roles for AT1bRs (294). The other AngII receptor, AT2R, is 34%
homologous compared to AT1R. Although AT2R is highly expressed during fetal
development (98), more restricted expression in adults has been demonstrated in
brain, adrenal gland, liver, kidney, myocardium, endothelium, uterus/ovary, and
adipose with upregulation of AT2R during some pathological states (61, 269).
1.1.2.2 Structure and signaling of angiotensin receptors
All AngII receptors are classic seven transmembrane G-protein coupled
receptors. The AT1R comprises 359 amino acids (Figure 1.2B) and has a
molecular mass of 41 kDa, though glycosylation at four extracellular residues
increases the mass to 65 kDa (124). Binding of AngII to AT1R requires
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interactions between the tyrosine residue of AngII and the Asn111 residue of the
third transmembrane domain as well as between the phenylalanine of AngII and
His256 of the sixth transmembrane domain (186). These transmembrane
residues of the AT1R are part of a transmembrane binding pocket present in
several GPCRs and the aromaticity of the Tyr and Phe residues of AngII may
facilitate these interactions. Multiple G protein-dependent signaling pathways
can be activated by AngII through the AT1R (Figure 1.3A). The AT1R initially
couples to Gq/11 to activate phospholipase C-β (PLC- β), an enzyme that cleaves
phosphatidylinositol (PIP2) to diacylglycerol and inositol triphosphate (IP3). IP3
then stimulates intracellular calcium (Ca2+) release, which is a key initiating event
in contraction of muscle cells. While this pathway is well-characterized, AT1R
signaling pathways vary by cell type. In vascular smooth muscle cells, AngIIstimulated AT1Rs can activate phospholipase C-γ through tyrosine
phosphorylation by intermediate tyrosine kinases, as the AT1R has no tyrosine
kinase activity of its own; tyrosine kinases activated by AT1Rs include c-Src,
focal adhesion kinase, Ca2+ -dependent kinases, Janus kinases, and receptor
tyrosine kinases (24, 67, 263). Activation of tyrosine kinases may play a role in
transactivation of the epidermal growth factor receptor through AngII-induced
phosphorylation of ADAM17, an enzyme that cleaves epidermal growth factor
from its heparin binding (110, 168). AngII may also transactivate other growth
factor receptors, such as platelet-derived growth factor or insulin-like growth
factor receptors, though these mechanisms are less clear (72, 250). In adrenal,
liver, kidney, and pituitary gland cells AT1R can activate Gi/o proteins that inhibit
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adenylyl cyclase and in rat portal vein myocytes AT1R can activate G12/13
proteins to activate L-type calcium channels (67, 156).
The AT1R can also activate signaling pathways independent of G-protein
coupling (Figure 1.3B). Interestingly, the AT1R is subject to biased agonism,
whereby these non-G-protein signaling pathways can be preferentially activated
by analogues of AngII such as [SII] (AngII with substituted
Sarcosine1,Isoleucine4, Isoleucine8) (11, 139). These G-protein independent
pathways involve the recruitment of β-arrestin as a result of phosphorylation by
GPCR kinases (GRKs) and result in receptor internalization and activation of
Extracellular signal regulated kinases 1/2 (ERK 1/2). In addition to ligandactivated signaling through G-protein coupled or G-protein independent
pathways, AT1Rs are also capable of ligand-independent activation, such as by
mechanical stress. Following up on initial reports that AT1R antagonists could
only partially attenuate mechanical-stress induced activation (282), more recent
studies have confirmed that AT1Rs undergo conformational changes during
mechanical stress that initiate ERK activation and result in cardiac hypertrophy
independent of AngII activation of the receptor, and administration of
candesartan reduces these effects, suggesting the conformation of candesartanbound AT1Rs is unable to respond to mechanical stress (166, 298).
The AT2R is 34% homologous with the AT1R and some of the structural
differences include additional cysteine residues in the N-terminal region and the
third extracellular loop which form stabilizing disulfide bonds in the AT1R but are
not present in the AT2R (190). The AT2R binds to Giα2 or Giα3 (292) and
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activates various phosphatases, including serine/phosphatase 2A (PP2A) and
MAPK phosphatase (MKP-1), through which it can functionally antagonize
signaling pathways activated by the AT1R (67). In cardiac myocytes, AT2R
activation can result in the release of arachidonic acid via stimulation of
phospholipase A2 (152) and it has also been reported in Ob1771 adipocytes that
activation of the receptor mediates the release of prostacyclin (PGI2), a
downstream product of arachidonic acid metabolism (61).
1.1.2.3 Regulation of angiotensin receptor function at the plasma membrane
Similar to many plasma membrane receptors, GPCRs undergo
internalization and subsequent degradation or recycling, which in the case of
GPCRs is agonist-dependent. In the case of AT1Rs, internalization is
downstream of β-arrestin signaling pathways which are G-protein independent
but requires receptor phosphorylation at the C-terminal tail by G-protein coupled
receptor kinases (GRKs) (192, 260). In vascular smooth muscle cells, AT1Rs
are associated with caveolae within 5 minutes of AngII stimulation and data
suggest AT1R internalization may in part be due to caveolae-mediated
endocytosis (118). Interestingly, the AT2R is a rare example of a GPCR that
does not undergo receptor internalization (265).
In recent years, the possibility of GCPR dimerization or oligomerization
has surfaced as a potential modulator of receptor signaling and several studies
suggest that AT1R signaling may be affected by homo- or hetero-oligomerization
(252). Oligomerization may play a role in directing the propensity of AT1R for Gprotein activation or ERK activation (106). Interestingly, inhibition of one AT1R
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within an homo-oligomer is sufficient to inhibit signaling of other receptors within
the complex, providing more evidence that receptor conformations can be altered
by formation of oligomers (136). Aggregation of AT1Rs can also occur at the cell
surface in response to environmental stimuli, including oxidative stress. Image
correlation spectroscopy (ICS) has revealed that AT1R oligomerization at the cell
surface increases in response to incubation with AngII, with further increases
upon treatment with H2O2, and oligomerization is associated with enhanced
AT1R-induced increases in intracellular Ca2+ (249). Potential pathological
relevance of AT1R homodimerization was demonstrated in hypertensive patients
with increased atherogenic risk factors who had increased levels of crosslinked
AT1R homodimers in monocytes capable of enhanced signaling (2). Potentiation
of AT1R signaling can also occur through heterodimerization with other
receptors, such as the cannabinoid type 1 (CB1R), β-adrenergic (β-AR), and
bradykinin 2 (B2R) receptors (3, 20, 219). AT1R/B2R heterodimers have been
implicated in the development of preeclampsia with studies demonstrating
increased levels of heterodimers that protect AT1R from oxidative stress-induced
inactivation (1). Oligomerization and heterodimerization present interesting
means through which AT1R signaling can be augmented, especially in response
to oxidative stress, with pathophysiological consequences and may lead to
additional therapeutic strategies.
Another mode of regulation of AT1R activity is through its distribution in
membrane microdomains within the plasma membrane. A recent study
fluorescently labeled lipid raft and non-raft domains and examined the
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redistribution and signaling capabilities of wild-type and mutant receptors upon
ligand-binding. Under resting conditions, AT1aRs were found to localize in lipid
raft domains, however AngII stimulation caused movement to non-raft domains
through Gq protein activation in HEK-293 cells (18).
Regulatory proteins can also bind to AT1R at the cell surface to direct
AT1aR internalization, such as angiotensin type 1 receptor-associated protein
(ATRAP) and the rat type 1 angiotensin II receptor associated protein 1 (ARAP1).
In mouse cardiomyocytes, ATRAP binds to an intracellular region of the receptor
and remains with the receptor as it is internalized after stimulation with AngII and
co-expression studies indicate that ATRAP plays an active role in decreasing
AT1aRs at the cell surface.(255) ARAP1, on the other hand, binds to a similar
region of the AT1aR but serves to enhance receptor recycling to the cell surface
in HEK-293 cells (99). Dysregulation of these regulatory proteins in disease
states may serve to potentiate AT1aR signaling and may present new
therapeutic targets.
1.1.2.4 Regulation of angiotensin receptor expression
Regulation of AT1aR expression has been examined primarily in the
context of vascular smooth muscle cells (VSMCs). Negative regulators of AT1R
expression include AngII itself, estrogen, reactive oxygen species (ROS), highdensity lipoprotein (HDL), and TGF-β1 (149, 180, 184, 272, 293). Pathogenic
stimuli such as hypercholesterolemia and high salt diets are positive regulators of
AT1R expression, which may contribute to the role of the RAS in diseases such
as atherosclerosis or hypertension (181-182, 185).
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Posttransciptional regulation of AT1R mRNA can occur through
stabilization or destabilization of AT1R mRNA. The AngII-mediated decay of
AT1R mRNA is dependent on the AUUUUA hexamer within the 3’ UTR which
results in a stem-loop structure required for the recruitment of the exosome
complex containing mRNA binding proteins that accelerate mRNA decay (23).
Proteins such as nuclear riboprotein S1-1 and p100 protein stabilize while
phosphorylated calreticulin destabilizes AT1R mRNA (173-174, 196).
Interestingly, insulin has also been identified as having AT1R mRNA-stabilizing
properties and enhanced AT1R expression induced by hyperinsulinemia may
contribute to the role of the RAS in the metabolic syndrome (183).
1.2.1 Adipose RAS
Components of the RAS required to synthesize and respond to AngII are
expressed in adipocytes. AGT expression was first discovered in peri-aortic
adipose tissue and subsequently confirmed in other adipose depots, including
both white and brown adipose tissue of rodents (39, 46, 94, 226) and white
adipocytes of humans (76). In fact, adipocytes are an important extra-hepatic
source of angiotensinogen, with 68% of the mRNA abundance observed in liver
(154). The expression and activity of renin and ACE in adipocytes is less clear.
While some groups have failed to detect renin mRNA transcripts in brown or
white adipocytes (76, 235), others have detected transcripts (97, 137) and renin
activity (230, 235). Similarly, reports of ACE expression and activity range from
undetectable (59) to low (131, 198). The fact that AngII is detectable in the
media of cultured adipocytes after 6 days of media changes suggests that while
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renin and ACE activity may be low in these cells, it is sufficient for processing
AGT to measurable levels of AngII (230). In whole adipose tissue in vivo, the
ability of other cell types such as preadipocytes, endothelial cells, and
macrophages to produce these components may contribute to the local
production of AngII. Additionally, other RAS components, such as prorenin
receptor and ACE2, are located in adipocytes and may regulate AngII production
(89, 100).
1.2.2 Adipose angiotensin receptors
Adipocytes have the ability to respond to either locally or systemically
produced AngII because they express angiotensin receptors. Initial ligandbinding assays by Crandall, et al. and Cassis, et al. demonstrated the presence
of AT1R on rat adipocytes using the selective AT1R antagonist, losartan, to
successfully compete for AngII binding (44, 59). Crandall, et al. observed AngII
binding adipose AT1Rs with an approximate affinity of 1 nM and receptor density
was greatest in epididymal, followed by retroperitoneal and mesenteric adipose
depots when corrected for differences in cell volume (59). Cassis, et al. similarly
observed AT1R affinity ranging from 0.3-0.6 nM with epididymal fat containing
the greatest number of receptor sites and interscapular brown adipose containing
the least (44). Both groups found that the selective AT2R antagonist, PD123319,
was unable to effectively compete radiolabelled AngII binding, suggesting low
expression levels of this receptor. Other groups have confirmed the expression
of AT1Rs with low or undetectable levels of AT2Rs in adipocytes derived from
rodents and humans (76, 97, 198). However, several groups have reported
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AT2R-mediated effects of AngII on adipocytes using AT2R antagonists, so the
functional relevance of AT2Rs cannot be ignored simply due to low expression
levels (61, 130). Expression of AT1bR was not detectable in adipose tissue (36).
1.2.2.1 Regulation of adipocyte angiotensin receptors during differentiation
Expression levels of the AngII receptors change throughout the process of
preadipocyte conversion to mature adipocytes, though there is controversy
regarding the nature of these changes. One group has shown that AT1aR
protein levels remain strongly expressed throughout the course of 3T3-L1
(murine embryonic fibroblast cell line capable differentiating to mature
adipocytes) adipocyte differentiation while AT2R expression is lost after 12 days
of differentiation (159). Similarly, our lab demonstrated that AT1aR mRNA
abundance increased significantly after 5 days of differentiation of 3T3-L1
adipocytes and remained elevated through 10 days (100). In studies of human
preadipocytes differentiated to mature adipocytes, results show transient AT2R
expression with either low levels of AT1R (163, 284) or increased AT1R as cells
became adipocytes (122). At least one study has shown increased protein
expression of AT2R with differentiation of human preadipocytes, and
interestingly, in this study AT1R mRNA abundance decreased throughout
differentiation even though the protein levels were unchanged, suggesting
reduced mRNA stability and that mRNA abundance may not be a reliable
indicator of protein expression (228). However there is widespread controversy
regarding the specificity of the antibodies of AT1Rs used in these studies for
western blot analyses (212). Despite a few instances to the contrary, most
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groups agree that the expression of RAS components to produce AngII are
increased with adipocyte differentiation (122, 163), though the regulation of
angiotensin receptors is more difficult to ascertain. Technical difficulties in
measuring angiotensin receptors (e.g., specificity of antibodies), the species of
adipocytes under study, or differences in expression levels resulting from
experimental conditions (i.e., components included in cell culture media, duration
of experiments, frequency of media changes, cellular production of AngII, etc)
may contribute to divergence in AngII receptor subtypes on adipocytes.
1.2.2.2 Regulation of adipose angiotensin receptors with obesity
Changes in gene and protein expression during adipocyte differentiation in
vitro may or may not reflect changes in vivo during states of over-nutrition, as the
relative contributions of adipogenesis and adipocyte hypertrophy to the obesity
phenotype are still unclear (15, 60). Early characterizations of AngII receptor
expression in lean and obese Zucker rats revealed reductions in AT1R
expression in liver but not in adipose depots (44). Another study using neonatal
monosodium glutamate (MSG) injection in rats as a model of adult-onset
adipocyte hypertrophy and insulin resistance demonstrated that AngII-AT1R
binding was decreased significantly with obesity although protein expression
increased markedly (199). While decreased ligand binding and increased protein
levels may suggest a defect in receptor binding or internalization, few studies
have followed up on these findings. In humans, a study comparing normal and
overweight patients observed no differences in AT1R mRNA abundance between
the different weight groups, but higher AT1R mRNA levels in visceral compared
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to subcutaneous adipose tissue (91). Interestingly, another study examining
AT1R expression among normotensive lean, obese normotensive, and obese
hypertensive patients found that AT1R expression was similar in normotensive
groups regardless of weight but was significantly increased in subcutaneous
adipose of obese hypertensives (79). This association between adipose AT1R
expression and hypertension could reflect a predisposition of persons with
increased AT1R in adipose to become hypertensive or an upregulation of
adipose AT1R in response to hypertension, and determining whether AT1R
upregulation is a cause or consequence could have important implications in
identifying at-risk populations or treating obesity-hypertension.
1.2.2.3 Regulation of adipose angiotensin receptors with age
Another important factor that may modulate adipose AT1R expression is
the process of aging, especially because aging is associated with increased
adiposity (256). One study demonstrated that adipose AT1R mRNA levels
decreased significantly between 4 and 12 weeks of age in male Wistar rats (6).
These data conflicts with a recent study demonstrating that AT1R mRNA
abundance was similar between rats aged 9, 12, or 20 weeks but was markedly
increased by 26 weeks of age (147). Interestingly, in this study protein levels of
AT1R were not reflective of the mRNA abundance but were elevated after 12
weeks of age and maintained through 26 weeks of age.
1.2.2.4 Regulation of adipose angiotensin receptors by AngII
AT1R expression is downregulated in response to AngII incubation in
VSMCs and in fact, most GPCRs exhibit reduced expression in response to

12

ligand-binding as a mechanism of self-regulation (149). In adipose tissue,
however, studies from our laboratory have indicated the opposite, that AngII
increased AT1aR expression (154). In this study, AT1aR mRNA levels were
elevated in epididymal adipose of AT2R deficient mice fed standard mouse
(chow) diet; however this increase was blocked by losartan. These data indicate
that deficiency of AT2Rs per se did not change AT1aR expression rather that
enhanced AT1aR signaling in the absence of AT2Rs resulted in increased
AT1aR mRNA expression. Moreover, infusion of AngII markedly increased the
expression of AT1aR mRNA in adipose tissue but not in liver, suggesting an
adipose-specific positive feedback loop wherein AngII increases the expression
of its own receptor. While adipose up-regulation by AngII may result from AngII
actions at adipocyte AT1aRs, this study used whole adipose tissue lysates to
isolate mRNA and it is possible that other cell types within adipose tissue
contributed to this effect. In the setting of obesity, where the systemic RAS is
thought to be elevated (57, 268), this positive feedback loop may be of particular
importance and result in further elaboration of AngII’s effects on adipocytes.
1.3 Evidence for a role of AngII in (patho)physiologic adipose tissue growth and
function
1.3.1.1 The process of adipocyte differentiation
Adipocyte differentiation comprises two distinct phases (Figure 1.4), the
first is the commitment to the adipocyte lineage wherein mesenchymal stem cells
(MSCs) become preadipocytes and the second is the terminal differentiation of a
preadipocyte into a mature adipocyte (60). In order for the commitment phase to
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progress, inhibitory Wnt and TGF-β signaling pathways must be interrupted and
stimulatory pathways involving zinc-finger protein 423 (ZFP423) and TCF7-like 1
(TCFL1) transcription factors must be turned on. Terminal differentiation begins
with exogenous adipogenic stimuli that induce transient upregulation of
CAAT/enhancer binding proteins (C/EBPβ and δ) which then induce PPARγ
expression, which acts as a master regulator of differentiation through
coordination with C/EBPα (280). PPARγ is a nuclear receptor activated by
polyunsaturated fatty acids and their derivatives that translocates to the nucleus,
heterodimerizes with retinoid X receptor (RXR), and binds PPAR response
elements (PPREs) in the DNA to recruit other co-activators to several target
genes. PPARγ and C/EBPα target genes include those for glycerophosphate
dehydrogenase, fatty acid synthase, acetyl CoA carboxylase, malic enzyme,
glucose transporters, insulin receptor, and fatty acid binding proteins (218).
Other transcription factors involved in adipocyte differentiation include Krox20,
Kruppel-like factors, Stat5A, and sterol-regulatory element-binding protein
(SREBP)-1c (237). In fact, adipocyte determination and differentiationdependent factor 1 (ADD1)/SREBP1 is another prominent regulator of
differentiation, as dominant negative ADD1/SREBP1 attenuated differentiation of
3T3-L1 cells (140). Adipocyte differentiation can be inhibited by several growth
factors, including FGF, PDGF, and EGF (including the membrane protein pref-1
which contains EGF-like repeats), which act by stimulating MAPKs that
phosphorylate and inactivate PPARγ (108, 239). Several other hormones and
growth factors act as adipogenic stimuli, however, and traditional differentiation
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cocktails used in vitro contain insulin, dexamethasone (glucocorticoid), insulinlike growth factor (IGF-1; present in fetal calf serum), isobutyl-1-methylxanthine
(IMBX; cAMP-elevating agent), and more recently, a PPARγ ligand (107).
Adipocyte differentiation can be regulated by nutritional status. Recent
studies suggest that adipogenesis is inhibited in the setting of obesity (101, 116,
197). Specifically, lipid accumulation in differentiated human preadipocytes is
inversely correlated to the subjects’ BMI as well as the size of adipocytes
obtained from collagenase digestion (116). Follow-up studies indicate that the
mechanisms involved may include sustained inhibitory canonical WNT signaling
pathways (101) or epigenetic changes resulting from hypertrophy-induced
hypoxia (141). Correspondingly, the numbers of adipocyte precursor cells in
adipose tissue increase 270% with high fat feeding, supporting the conclusion
that adipocyte differentiation is impaired, not the availability of precursor cells
(155). This suppression of adipocyte differentiation causes the remaining
adipocytes to accumulate more lipid, thus contributing to adipocyte hypertrophy
and its consequences, such as insulin resistance (13-14). While these results
provide interesting new insights into mechanisms of adipocyte hypertrophy, they
are seemingly incongruent with other reports of increased adipocyte cell numbers
in obese subjects (80, 143, 243), demonstrating that more research is necessary
to understand the dynamics of adipogenesis in obesity. Conversely, in the
setting of nutrient deprivation, adipocyte differentiation may be enhanced.
Calorie-restriction in rats for 2 or 25 months upregulates adipogenic markers,
such as PPARγ, C/EBPα, and adiponectin and consequently adipocyte size was
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reduced in these rats (295). Other studies indicate that calorie-restriction of 3T3L1 cells causes the cells to revert to a proliferative state (213) which may or may
not be conducive to adipocyte differentiation, again indicating the need for further
research into these mechanisms of adipogenesis.
1.3.1.2 Role of AngII in adipocyte differentiation
There are several methods that have been used to study the process of
adipocyte differentiation, including preadipocyte differentiation ex vivo, clonal
preadipocyte cell lines capable of adipocyte differentiation, isolated primary
adipocytes, or adipose tissue explants. In the case of the RAS, these methods
could be employed in the absence or presence of AngII and/or inhibitors of the
RAS such as ACE inhibitors or angiotensin receptor blockers (ARBs). One
caveat, however, regarding the use of ARBs to study adipose tissue
development is that some ARBs have been found to stimulate PPARγ,
independently of AT1R blockade (22, 216, 231). Two independent reports were
published in 2004 that certain ARBs have PPARγ-agonizing properties
independent of AT1R signaling (22, 231), which has been confirmed by
subsequent studies in AT1aR-/- mice (216). Telmisartan, irbesartan and
candesartan consistently exert PPARγ-agonism while eprosartan, valsartan, and
losartan have little or no ability to do so (13, 22, 54, 78, 86, 123, 231, 245, 296).
At least one study, however, has identified the EXP3179 metabolite of losartan
as a partial PPARγ agonist (232). These properties of ARBs must be considered
when interpreting investigations of the role of AngII or the AT1R in the process of
adipocyte differentiation.
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Few studies have examined the effects of AngII on the initial commitment
step in which MSCs commit to the adipocyte lineage (Table 1.1). One group
incubated commercially available human mesenchymal stem cells with 3 cycles
of adipocyte induction medium for 3 days followed by 3 days of adipocyte
maintenance medium, including incubation with AngII alone or in combination
with valsartan or PD123319 throughout the 18-day period and found that AngII
decreased PPARγ, FAS, and lipid accumulation (163). This anti-adipogenic
effect was mediated through the AT2R, as valsartan further reduced the levels of
PPARγ and FAS, indicating a pro-adipogenic effect of AngII through the AT1R. It
is difficult, however, to determine if AngII influenced the initial commitment step
or the terminal differentiation step because the treatments were maintained
through the entire differentiation period. In addition to influencing commitment to
preadipocytes, AngII may also affect preadipocyte proliferation as it has been
shown that AngII increases human preadipocyte proliferation through AT1Rmediated increases in cyclin D expression (58). AngII has also been reported to
increase mature adipocyte cell numbers through the AT1R in serum-free
conditions by increasing cell division, however it is unclear whether these results
are relevant in vivo (225).
Several studies have used preadipocytes isolated from the stromal
vascular fraction of whole adipose tissue digested with collagenase, with some
investigators reporting an anti-adipogenic effect of AngII (85, 122, 229)(Table
1.1). Of these studies, only Janke, et al. determined the role of AT1R versus
AT2R in their observed effects, demonstrating that irbesartan administration in
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the absence of exogenous AngII increased lipid accumulation while the AT2R
antagonist had no effect (122). However, as described above, irbesartan has
AT1R-independent effects, complicating interpretation of these data. Mouse
fibroblast-like embryonic cell lines (Ob1771, 3T3-L1) have been valuable tools
employed to study AngII’s role in adipocyte differentiation because they offer
consistency in differentiation that is difficult to achieve from human-derived
samples. However, these cell lines do not allow investigators to define the
contributions of preadipocytes derived from different regional locations. One of
the first studies in this field found that AngII reduced adipocyte differentiation in
OB1771 cells through the AT2R (61). However, these results are also
controversial because others found that exogenous (130) and endogenous (114)
AngII increases lipid accumulation and markers of adipocyte differentiation. In
these studies both AT1R and AT2R antagonists reduced FAS and GPDH
enzyme activities (130) or lipid accumulation (114). Changes in adipocyte size
and markers of adipocyte differentiation have also been studied in vivo, and
these will be discussed later in terms of the role of AngII in the regulation of body
weight.
1.3.2.1 The pathophysiology of obesity
The World Health Organization classifies people as obese with a body
mass index (BMI) greater than 30 and overweight with a BMI of 25-29.9. The
latest data from the National Health and Nutrition Examination Survey in 20092010 indicated that 35.7% of adults and approximately 17% of children
nationwide are obese (187). As recently as 1990, no state had a prevalence of
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obesity greater than 15%, whereas in 2010 all states had obesity rates above
20%, including 36 states above 25%, indicating the recent dramatic increases in
obesity (187). Obesity is a component of the metabolic syndrome, which is a
cluster of risk factors that greatly increase the risk for cardiovascular disease and
includes elevated waist circumference, blood pressure, fasting blood glucose,
triglycerides, and reduced HDL (8). Visceral obesity is the central component of
the metabolic syndrome and is independently associated with each of the other
factors (42). Despite the strong associations between obesity and disease,
about 15% of obese individuals are unaffected by obesity-associated disorders
and manage to possess “metabolically healthy” adipose tissue, which is thought
to be due to a high number of small (non-hypertrophied, non-hypoxic, or noninflamed) adipocytes (26).
While caloric intake in excess of energy requirements is the basis of
obesity, it is a multi-factorial disease state that can be influenced by various
genetic and environmental factors, including physical activity, regulation of
satiety, addictive eating behaviors, hormonal imbalance, fetal programming, or
even disturbances in intestinal microbiota.

Regardless of the causes of obesity,

changes in adipose tissue growth, function, and remodeling dictate whether an
obese individual develops obesity-associated disorders. During the development
of obesity, excess caloric intake results in increases in adipocyte size
(hypertrophy), however as discussed previously, the contributions of precursor
recruitment, commitment, proliferation, and differentiation are still under
investigation (248). Obesity is associated with increased macrophage infiltration
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into adipose tissue (277) resulting from inappropriate adipose tissue remodelling
to accommodate larger adipocytes (248). Adipose tissue inflammation combined
with ectopic lipid accumulation in non-adipose tissues connect obesity with other
components of the metabolic syndrome to increase risk of cardiovascular
disease (170).
1.3.2.2 Genetic evidence for a role of AngII in the development of obesity
Polymorphisms have been identified in the genes for AGT, ACE, and
AT1R that result in either reduced or increased functions of these proteins, with
possible implications in the development of obesity and related disorders. Three
commonly studied mutations in the RAS include M235T AGT mutation, which
results in higher plasma AGT levels (126), the A1166C AT1R mutation, which
increases responsiveness of the AT1R (27), and the insertion/deletion (I/D) ACE
mutation, in which D/D individuals have double the plasma ACE activity of I/I
individuals (214). The Olivetti Prospective Heart Study of 959 Italian men
examined associations of these three mutations with BMI, body fat distribution,
and obesity-associated hypertension (246). This study found no association
between the AGT or AT1R mutations with any of these parameters, however
individuals with the D/D genotype in the ACE gene were significantly more likely
to be overweight and have abdominal obesity. Other studies have also found
significant associations between the D allele and increased BMI (275) and
individuals with at least one D allele in the ACE gene were more likely to have at
least one of the following; obesity, hypertension, hyperlipidemia, or diabetes
mellitus (266). However, in the Health Aging and Body Composition Cohort
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Study, the I/I genotype of the ACE mutation has also been positively associated
with BMI despite resulting in lower serum ACE levels than the D/D genotype
(146). In contrast to the Olivetti Prospective Heart Study, the Heritage Family
study did find that mothers with the T allele of the M235T AGT mutation had
significantly greater fat mass than mothers homozygous for the M allele (211).
Interestingly, AGT secretion from isolated adipocytes was not affected by the
individual’s BMI, obesity, body fat, blood pressure, or AGT polymorphism, though
adipocyte size was increased in individuals homozygous for the T allele (204).
Several studies have failed to find any associations between RAS gene
polymorphisms and obesity or BMI, possibly due to the population under study
and the population size (84, 167, 267).
Metabolic studies on mice lacking one of the major components of the
RAS (AGT, renin, ACE, AT1aR, AT2R) have demonstrated reductions in body
weight and adiposity (Table 1.2), as well as improved insulin sensitivity. These
results suggest that AngII may play a role in the development of adipose tissue
and consequently the development of obesity and obesity-related insulin
resistance. AGT-/- mice exhibit reductions in body weight at weaning and
throughout 46 weeks of age when maintained on either standard murine diet or
when fed a high fat diet (65% fat) (160). Differences in body weight were due to
lower body fat and hypotrophy of adipocytes, which were attributed to increased
locomoter activity in AGT-/- mice. Of note, however, these mice were of the ICRCD1 strain (not the C57BL/6 typically used) and wild-type control mice were nonlittermates, which may be of significance because wild-type ICR-CD1 mice were
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resistant to diet-induced obesity. C57BL/6 mice lacking the Ren1c gene for renin
also demonstrate lower body weights, both on standard murine diet and when
fed a Western diet (42% fat) (253). Food intake, activity, and expression of
adipogenic genes in epididymal adipose tissue were not regulated by renin
deficiency under HF conditions; however, Ren1c-/- mice had increased heat
generation and decreased fat absorption, which may have contributed to the
body weight phenotypes. Additionally, AngII infusion (1.5 ug/day) in Ren1c-/mice restored body weight and fat mass to levels of WT mice, implying that the
effects of renin deficiency were due to reduced production and actions of AngII
and not due to AngII-independent metabolic effects of renin. ACE-/- mice fed
standard murine diet displayed reduced body weight and fat mass with improved
glucose tolerance; however, this study did not investigate the effects of ACE
deficiency when mice were fed a high fat diet (125). Wildtype and ACE-/- mice
had similar locomoter activity but ACE-/- mice exhibited increased total and
resting energy expenditures, which was attributed to increased fatty acid
metabolism in liver. These various models of reducing AngII synthesis indicate
that AngII acts as a positive regulator of weight gain and adiposity; however,
mechanisms for these effects are unclear and vary between models.
Mouse models of angiotensin receptor deficiencies have also been
investigated for metabolic effects with less consistent results on body weight and
adiposity. Initial studies by Kouyama, et al. showed AT1aR-/- mice have similar
body weights compared to littermate controls when fed standard murine diet;
however, they are partially protected from high fat (60% kcal as fat) diet-induced
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obesity and glucose intolerance (144). Food intake was not influenced by AT1aR
deficiency, but body temperature and O2 consumption were increased.
Adipocytes from high fat-fed AT1aR-/- mice were modestly hypotrophic.

Another

group, Yamamoto, et al., also studied AT1aR-/- mice fed standard murine diet
(4.8 % fat) diet and observed increases in body weight beginning at 3 weeks of
age and persisting through 24 weeks of age due to hyperphagia in AT1aR-/- mice
compared to controls (281). Consistent with results of Kouyama et al., in a pairfeeding study in which AT1aR-/- mice were limited to the same food intake of WT
controls, AT1aR-/- mice exhibited reductions in body weight and fat mass (281).
Both ad libitum fed and pair-fed AT1aR-/- had decreased levels of the
anorexigenic peptide corticotrophin-releasing hormone (Crh) and luciferase
assays confirmed regulation of hypothalamic Crh expression by AngII. High fat
fed mice in this study, however, did not exhibit hyperphagia or differences in
body weight. The reasons for the differences between these results and those of
Kouyama, et al. are not entirely clear; however, Yamamoto, et al. describe
different housing conditions as a possible confounder between studies.
Surprisingly, mice lacking AT2R have also been demonstrated to exhibit reduced
body weight and fat mass following high fat feeding (289). Improvements in
insulin resistance (calculated as a product of the area under plasma glucose and
insulin curves as plotted from a glucose tolerance test) were observed in AT2R-/mice fed either a low fat or high fat diet. The results of Kouyama, et al. and
Yvan-Charvet et al. are noteworthy because data suggests that AT1aR and
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AT2Rs may have similar or overlapping functions in adipocytes, which is contrary
to other cell types where AT1aR and AT2R signaling are in direct opposition (67).
Similar studies to those described above have been performed in AT1aR-/or AT2R-/- mice on a hypercholesterolemic background, namely mice lacking
apolipprotein E (ApoE-/-) or low density lipoprotein receptor (LDLR-/-).
Hypercholesterolemia has been demonstrated to stimulate the RAS, increasing
circulating AGT and angiotensin peptides (65) which may result in more
pronounced effects of receptor deficiencies in a hypercholesterolemic setting.
AT1aR/ApoE double knockout mice had significantly reduced fat mass and
adipocyte size compared to ApoE-/- controls when fed standard murine diet (262).
Reductions in adipocyte size in double knockout mice were associated with
increased adipogenesis as evidenced by increased PPARγ, C/EBPα, and aP2
mRNA abundance, suggesting that AngII inhibits adipocyte differentiation
through the AT1aR in ApoE-/- mice (262). In another study by the same group,
there was no effect of AT2R deficiency in ApoE-/- mice fed standard murine diet
(121). However, with 4 weeks of high cholesterol diet (1.25% cholesterol)
AT2R/ApoE-/- mice displayed increased fat mass, reduced adipocyte numbers,
and reduced PPARγ mRNA abundance, suggesting that AngII promotes
adipogenesis through the AT2R in ApoE-/- mice fed a high cholesterol diet (121).
It is unclear why hypercholesterolemia causes these receptors to oppose one
another when they appear to have similar effects in C57BL/6 mice fed low or high
fat diets.
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1.3.2.3 Regulation of body weight by pharmacologic blockade of the RAS
Another model for investigating the role of angiotensin receptors in the
development and function of adipose tissue involves administration of
pharmacological antagonists to various animal models rather than genetic
ablation of the receptors. Use of antagonists is more relevant to the treatment of
human disease and an additional benefit is that the receptors are generally
antagonized in adult mice, eliminating developmental artifacts that may
contribute to adult phenotypes in murine knockout models. ACE inhibitors are
one class of drug that have been extensively studied in animal models. SpragueDawley rats fed standard rat diet and administered perindopril in the drinking
water either from birth through 10 weeks of age exhibited reduced fat mass (162,
278). Wistar rats fed either standard or a high fat diet (35% kcal as fat)
containing enalapril also exhibited reduced fat mass, though food intake was also
reduced in enalapril-treated rats (223). Mice fed a high fat diet (roughly 50% kcal
as fat) for 12 weeks prior to captopril administration experienced dramatic weight
loss when administered captopril that was maintained through 12 additional
weeks of high fat feeding (206). In mice administered captopril, reductions in fat
mass were attributed to increases in lipolysis and fatty acid oxidation both in liver
and adipose tissues; however, food intake was also reduced in captopril-treated
animals.
ARBs have also been extensively studied in regard to their ability to
modulate adiposity, and given the previous discussion of the non-specific
PPARγ-agonism of certain ARBs, it is not surprising that several studies using
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telmisartan, irbesartan, and candesartan in animal models have demonstrated
reductions in body weight, fat mass, and adipocyte size concurrent with
upregulation of PPARγ and/or its target genes (12, 247, 296). The PPARγstimulating properties of valsartan seem to be less clear because while one study
found no evidence of PPARγ-agonism (78), other studies using valsartan
demonstrate reductions in fat mass and adipocyte size in Sprage-Dawley rats fed
a high fat, high carbohydrate diet for 3 months (247) as well as upregulation of
PPARγ mRNA abundance in adipose tissue of diabetic KK-Ay mice (262). A
study using temocapril (ACE inhibitor) and olmesartan (not a PPARγ ligand) in
rats fed a fructose-rich diet, which is a non-obese model of insulin resistance,
observed no changes in body or fat mass with either drug, but did see reductions
in adipocyte size (88). Sprague-Dawley rats administered losartan (not a PPARγ
ligand) at 3 months of age for 2 weeks had attenuated weight gain, smaller
adipose pads, and reduced cell size(59). Losartan administered to aged rats fed
standard diet between the ages of 24 and 30 months failed to affect body weight
or fat mass, which supports the lack of PPARγ-agonism by losartan, (43). The
results with non-PPARγ-agonist ARBs suggest there may be an effect of AT1R
blockade on adipose tissue growth; however, reductions in fat mass observed
with valsartan, olmesartan, or losartan are modest and do not always translate to
differences in body weight.
1.3.2.4 Regulation of body weight by AngII infusion (elevated RAS)
Deficiency of major RAS components consistently results in reduced body
weight and adiposity, possibly due to reduced action of AngII at certain cell types.
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However, models whereby AngII is increased by chronic infusion also
demonstrate paradoxical reductions in body weight and adiposity. Initial studies
in rats demonstrated that infusion of AngII (500ng/kg/min) to Sprague-Dawley
rats for 14 days reduced body weight due to reductions in food intake while coadministration with losartan, but not hydralazine, could attenuate these effects
(34). Cassis, et al. confirmed the blood pressure-independent and dosedependent reductions of body weight caused by AngII infusion in rats (47).
Further studies by this group demonstrated reductions in food intake in AngIIinfused rats (77). Interestingly, intracerebroventricular (icv) infusion of AngII
caused reductions in body weight similar to peripheral AngII infusion, and while
food intake was reduced when AngII was infused icv, pair-fed rats also lost
weight indicating that reduced food intake alone is not the sole mechanism for
AngII regulation of body weight (68). This study and others (77) observed
increased sympathetic nerve activity in brown and white adipocytes, which could
increase energy expenditure and lipolysis, respectively, to contribute to AngIIinduced weight loss. Lipolysis was quantified in vivo in AngII-infused SpragueDawley rats using a microdialysis technique to measure interstitial glycerol levels
and results indicated that AngII stimulated lipolysis in white adipose tissue in an
AT1aR-dependent manner (37). AngII-induced lipolysis in this study was also
blocked by a nonselective β-adrenergic antagonist, suggesting interplay between
presynaptic β-adrenoreceptors and AT1aRs.
The possible role of AngII to stimulate lipolysis has been examined in
humans with conflicting studies demonstrating no effect (264), a weak stimulatory
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effect (28-29) or an inhibitory effect of AngII on lipolysis (30-31, 95-96). In one
study of healthy male subjects, both sub-pressor and pressor doses of AngII
infusion failed to alter whole-body lipolysis rates, plasma free fatty acids, plasma
insulin, or plasma norepinephrine concentrations (264). In contrast, subsequent
studies utilized a microdialysis technique to study tissue-specific, rather than
whole-body effects of AngII or ARB administration on blood flow (ethanol dilution
technique) and lipolysis (glycerol accumulation). Initial studies by Boschmann, et
al. demonstrated slight reductions of blood flow in response to AngII and a failure
of AngII to change glycerol concentrations, though accumulation of glycerol was
expected as a result of reduced blood flow. Thus, the authors concluded that a
lack of change in glycerol levels in response to AngII suggests that AngII
inhibited lipolysis (30-31). However, follow-up studies by this same group
contradicted these results and revealed weak stimulation of adipose lipolysis by
AngII (0.1 – 1.0 µM) (28-29). Studies of the lipolytic effects of AngII by another
group also found that doses of AngII that reduced blood flow inhibited lipolysis,
while higher doses of AngII paradoxically stimulated lipolysis (95-96). A
randomized, double-blind crossover study in which obese men were treated with
either placebo or irbesartan for 10 days with a 2-4 week wash-out period
between treatment phases found that blockade of endogenous AngII with
irbesartan modestly reduced isoproterenol-induced glycerol production in
adipose tissue, indicating an enhancement of lipolysis by AngII (28). While to
this point most groups speculated that AngII acted on presynaptic AT1Rs on
sympathetic nerve terminals innervating adipose tissue to modulate
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norepinephrine production and thus influence β-adrenergic stimulation of
lipolysis, Goossens, et al. performed a study in isolated adipocytes and found
that AngII administration reduced glycerol production in an AT1R-dependent
manner, implying a direct role for AngII at adipocyte AT1Rs (95). Unfortunately,
differences in results from these studies examining AngII regulation of lipolysis
have not been resolved, potentially influenced by direct versus indirect effects of
AngII on lipolysis.
1.4 The role of AngII in obesity-induced hypertension
1.4.1 The association between obesity and hypertension
(73)[171]The Framingham Heart Study indicated that 78% of hypertension
cases in males and 64% in females can be directly attributed to obesity, yet the
mechanistic links between the obesity and hypertension remain unclear (90).
There is also a linear relationship between BMI and hypertension risk, such that
the odds ratio for the presence of hypertension is 1.7 for overweight individuals,
2.6 for those with a BMI of 30-34.9, 3.7 with a BMI of 35-39.9, and 4.8 with a BMI
over 40 (179). While effective antihypertensive medications are available, the
prevalence of resistant hypertension, referring to hypertension that persists when
treated with more than 3 antihypertensive agents, is expected to increase as the
population becomes heavier and older (38), highlighting the need for either more
effective medications than those currently available or better identification of
specific characteristics of patient populations governing their responsiveness to
medications.(38)[174]
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1.4.2 Mechanisms of obesity-induced hypertension
Postulated

mechanisms

linking

obesity

to

hypertension

include

renal/hemodynamic changes, elevated levels of adipokines, insulin resistance,
increased reactive oxygen species, enhanced sympathetic nervous activity, or
activation of the RAS (71, 148, 178). Impaired kidney function brought on by the
development of glomerulosclerosis or compression of the kidney by abdominal
visceral fat could result in impaired pressure natriuresis and increased blood
volumes seen in obese patients.

While increased intra-abdominal pressure

induced by artificial means (balloon) in dogs did result in increased blood
pressure, the mechanisms and translatability of this study to human obesity are
unclear (25).

Insulin resistance is part of the metabolic syndrome and is

frequently present in obese-hypertensive patients; however, a direct role for
insulin or hyperinsulinemia to promote high blood pressure has not been
demonstrated (9, 105).

Factors produced by adipocytes, termed adipokines,

represent an area of investigation that may identify mechanisms linking obesity to
hypertension.

Adipokines linked to the development of hypertension include

resistin, adiponectin, leptin, and angiotensinogen (193, 208, 257, 286). Resistin
is an adipose-derived vasoconsitrictor involved in insulin resistance, though its
role in non-diabetic hypertension is unclear (254). Adiponectin is a protective
hormone associated with insulin sensitivity that can act as a vasodilator by
upregulating eNOS production and reducing vascular reactive oxygen species
(193), and obesity-associated hypoadipnectinemia may promote increases in
blood pressure through ROS-induced endothelial dysfunction (148). Leptin is an
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anorectic protein hormone secreted by adipocytes, which acts on the
hypothalamus to suppress food intake and can also stimulate sympathetic nerve
activity to organs implicated in control of the cardiovascular system. The role of
leptin in obesity-hypertension is complex because while hyperleptinemia and
resistance to the anorectic properties of leptin are characteristic features of
obesity, the sympathetic stimulation by leptin appears to be maintained (209).
1.4.3 The RAS as a link between obesity and hypertension
While all of the above-mentioned mechanisms may contribute to obesityinduced hypertension, the RAS is another important candidate that has been
suggested to contribute to obesity-induced hypertension since adipocytes
express all components needed to synthesize and respond to AngII (48). The
systemic RAS has been demonstrated to be activated in rodent and human
obesity (32, 271), and inhibitors of the RAS are effective treatments to reduce
blood pressure in obese rodents and humans (33, 142). In one study of 4 black
populations, plasma AGT levels were highly correlated to BMI and interestingly,
variation in BMI accounted for 90% of variation in AGT levels between
populations (57). Another group extended these findings by demonstrating a
significant correlation between plasma AGT levels and obesity (268). Adipose
tissue distribution may play an important role in the relationship between BMI and
plasma AGT levels since AGT mRNA abundance from visceral adipose tissue,
but not subcutaneous, positively correlated with BMI (92). However, conflicting
results have been obtained (283).
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Data from animal models demonstrate that adipose-derived RAS
components contribute to circulating levels of AngII and provide further evidence
that the RAS is activated with obesity.
demonstrated

that

AGT

expression

Initial studies by Massiera, et al.
limited

to

adipocytes

(AGT

was

overexpressed in adipocytes of AGT null mice) restores non-detectable plasma
AGT levels of AGT null mice to 20-30% of that of wild-type mice (161). This was
confirmed by our group using a model of adipocyte AGT deficiency in mice in
which plasma AGT levels were reduced roughly 25% (21). In both studies by
Massiera, et al. and Yiannikouris, et al., changes in AGT corresponded to
changes in blood pressure, implicating adipose-derived AGT influences blood
pressure.

Our laboratory has demonstrated elevated concentrations of

angiotensin peptides in plasma from rats (32) and C57Bl/6 mice made obese
from consumption of a high fat diet (100). Moreover, obesity in both rodent
models was associated with elevated blood pressure that was normalized by
losartan, implicating the actions of AngII at the AT1R as a major contributor to
obesity-induced hypertension (33).
1.5 The role of AngII and adipose in vascular diseases
1.5.1 The development, risk factors, and treatments of vascular disease in
humans
Heart disease and cerebrovascular disease were among the top four
leading causes of death in 2010 in the United States, leading to over 720,000
deaths combined (176).

Atherosclerosis, an underlying cause of these

conditions, is an inflammatory disease in which an initial endothelial insult results
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in accumulation of cholesterol-rich macrophage foam cells in the sub-endothelial
space of the aortic wall and develops into a plaque prone to thrombus (207).
Atherosclerosis and arterial thrombosis can lead to restricted blood flow to the
heart (coronary artery disease; CAD), peripheral artery disease (PAD), or
cerebral ischemia (stroke) (115).

Risk factors for atherosclerosis include

components of the metabolic syndrome previously discussed (Section 1.2) as
well as physical inactivity, smoking, poor diet, heavy drinking, stress, sleep
apnea, age, and family history (115). Endothelial dysfunction, oxidation of LDL,
inflammation, apoptosis, and coagulation are pivotal processes in the
development of atherosclerosis, highlighting the participation of many different
cell types ranging from vascular wall cells to immune cells to platelets and the
need for cell-specific models to study each component of this disease.
Aortic aneurysms and aortic dissections were responsible for over 10,000
deaths in 2010, and are estimated to be present in approximately 1.1 million
people (176, 261). AAAs are defined as a permanent dilation of the aorta in
which the diameter is 50% greater than a normal, healthy infrarenal aorta, or at
least three centimeters, and are characterized by thickening and inflammation of
the adventitial layer of the aortic tissue (129). Risk factors for AAA formation
include smoking, male gender, visceral obesity, and age > 65 years old (238).
Experimentally induced AAAs, including those induced by infusion of AngII,
exhibit elastin degradation within the medial layer of the aortic wall and
macrophage infiltration into this region (224). The success of pharmacological
RAS antagonists in reducing atherosclerosis (81, 135, 172, 217, 288) and
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experimental AAAs (102, 169, 261) have initiated studies into the role of AngII as
an inflammatory stimulus contributing to the development of these vascular
pathologies.
1.5.2 The role of AngII and angiotensin receptors in vascular diseases
Several animal models reproduce findings in humans that ACE inhibitors
reduce the severity of atherosclerosis (4, 50, 53, 145). Hypercholesterolemia
significantly increases the production of angiotensin peptides in a process
mediated by AT1aRs, though the exact mechanism is unknown (65).
laboratories

demonstrated

that

chronic

infusions

of

AngII

Our

promoted

atherosclerosis in LDLR-/- and ApoE-/- mice (62-63). During the course of these
studies, AAAs were discovered in a significant number of mice and infusion of
AngII has become a well-established model of AAA formation used by several
investigators.

Further experiments showed that AngII infusion promotes the

formation

AAAs

of

independent

of

increases

in

blood

pressure,

as

norepinephrine infusion elevated blood pressure to the level of an AngII-infused
mouse, but had no effect on the aortic diameter (45).
Mechanism(s) through which AngII promotes these vascular diseases are
under intensive investigation.

A consistent finding is that AngII-induced

atherosclerosis and AAAs in mice are markedly reduced in mice with whole body
AT1aR deficiency (49, 65, 276), indicating that both pathologies are AT1aRmediated. In contrast, there is controversy regarding the role of AT2R in these
AngII-mediated vascular diseases (64-65, 120, 128). In LDLR-/- mice fed a high
fat, cholesterol containing diet for 12 weeks, deletion of AT2R had no effect on
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atherosclerosis (65). In contrast, another study found that AT2R deficiency in
ApoE-/- mice fed a high fat/cholesterol diet for 10 weeks augmented the
development of atherosclerosis (120).

These results suggest the AT2R is

protective against atherosclerosis and thus enhanced activation of this receptor
in AT1aR deficient mice contributes to reduced lesion formation, and accordingly,
the effects of AT1aR antagonism are mitigated in AT2R deficient mice (120).
Conflicting results were found using AT2R pharmacologic blockade with the
compound PD123319 in chow-fed ApoE-/- mice infused with AngII, where the
compound either had no effect (128) or exacerbated atherosclerosis (64). The
various study conditions and experimental designs used by these groups
compromise the ability to interpret these results.
While data are in agreement with a pivotal role of AT1R in AngII-induced
atherosclerosis and AAAs, the cell type(s) mediating these effects remain
unknown. Bone marrow transplantation studies using AT1aR-/- mice as donors
and wild-type LDLR-/- mice as recipients (effectively creating leukocyte-specific
AT1aR-/- mice) showed only a modest reduction in atherosclerosis and no effect
on AAA formation, suggesting that leukocyte AT1aR are not the primary target of
AngII to promote these pathologies (49).

Similarly, deficiency of AT1aR on

endothelial cells or smooth muscle cells also fails to affect the development of
atherosclerosis or AAAs (unpublished observations), however endothelial
AT1aRs do appear to mediate the development of ascending aortic aneurysms
(212). Adipose tissue surrounds the length of the aorta in a way that no fascial
layer separates adipocytes from the vascular wall.
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Adipocytes are gaining

interest as a source of inflammatory mediators and present another cell type
through which AngII may induce atherosclerosis and AAAs.
1.5.3 Role of adipose in the development of atherosclerosis
Over the past several years, the idea of crosstalk between perivascular
adipose tissue and blood vessels has given rise to what is known as the “outside
to inside” signaling mechanism of atherosclerotic plaque formation. Investigators
hypothesize that adipocytokines and chemokines released by adipose tissue can
enhance various aspects of plaque development, such as endothelial
dysfunction, vascular smooth muscle cell proliferation, and infiltration of
inflammatory cells (273). Adipose tissue surrounds most blood vessels, including
the coronaries and the aorta, and the distance between the two is less than 0.1
mm with no anatomical barrier to inhibit the diffusion of adipocytokines (109,
210).

Early studies from our laboratory demonstrated that the presence of

perivascular influenced the contractility of rat aorta to several vasoactive agents,
including AngII (240).

Since this initial report, several lines of evidence

demonstrate that perivascular adipose-derived vasoactive factors influence the
tone of blood vessels, demonstrating a functional link between these two tissues
(151, 274).
The association between perivascular adipose tissue and atherosclerosis
has gained increasing attention. In a segment analysis, pericoronary fat was
associated with coronary atherosclerosis independent of overall epicardial
adipose volume (158) and there is a higher incidence of plaques on the
epicardial side of coronaries versus the myocardial side (205), suggesting a
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causative role for epicardial adipose in plaque formation. Additional studies have
revealed that pericardial fat volume, measured by cardiac computed tomography
(CT), is associated with high-risk coronary lesions, independent of both BMI and
the extent of plaque burden, supporting the conclusion that adipose has a local
effect on the vessel (227). In fact, regions with low pericardial adipose had no
high-risk coronary lesions (227).
More importantly, several studies have demonstrated that epicardial and
perivascular adipose secrete more inflammatory mediators than other adipose
depots (17, 51, 109, 165) and these proinflammatory mediators are increased
with high fat feeding and obesity (51, 244).

Specifically, secretion of the

chemokine MCP-1, a macrophage chemoattractant with a pivotal role in the
development of AngII-induced and human vascular diseases (117, 157), is
upregulated 10-40 fold in perivascular adipose compared to perirenal and
subcutaneous fat (51). Our lab has also demonstrated that MCP-1 secretion
from abdominal peri-aortic fat is elevated in mice fed a high fat diet (203).
Interestingly, another technique has recently been developed to study the role of
adipose

tissue

in

the

development

of

atherosclerosis

which

involves

transplantation of adipose depots between mice. Initial studies by Ohman, et al.
demonstrated that the transplantation of visceral, but not subcutaneous, adipose
tissue into the subcutaneous region of ApoE-/- increases atherosclerotic lesion
formation through elevation of systemic adipocytokines, in the absence of
confounding factors such as high fat feeding, obesity, or diabetes (189).
Subsequent studies by this group revealed that transplantation of visceral
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epididymal adipose directly adjacent to the right common carotid artery
dramatically increased atherosclerosis, though again subcutaneous adipose had
no effect (188). These studies by Ohman, et al. provide further evidence that
adipose tissue surrounding vessels can contribute to lesion development,
possibly through “outside to inside” signaling mechanisms, though it remains to
be determined if the AngII/AT1R axis activates these pathways.
1.5.4 Role of adipose in AAA formation
The Health in Men Study of more than 12,000 men found that both waist
circumference and waist-to-hip ratio are positively associated with AAA size, after
adjustment for other risk factors such as age, dyslipidemia, smoking,
hypertension, coronary heart disease, and diabetes mellitus (93).

Moreover,

more severe aneurysms (those≥ 40mm compared to 30 mm) had an even
greater association, suggesting that obesity may play a role in the severity as
well as the development of AAA (93). Data from our laboratory corroborates
findings that obesity promotes aneurysm formation (203) and furthermore that
weight loss attenuates the adventitial expansion of formed AAAs in a model of
AngII-induced AAAs in high-fat fed mice (202). Police, et al. demonstrated in
both genetic (ob/ob) and high fat diet-induced obesity models that obesity
increases AngII-induced AAA formation (203).

Somewhat surprisingly, male

C57BL/6 mice fed high fat diet for 4 months displayed similar aneurysm
incidence to hypercholesterolemic LDLR-/- mice. These results were attributed to
the inflammatory nature of abdominal peri-aortic fat compared to thoracic
abdominal fat, as AAAs develop specifically in the abdominal region where the
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surrounding

adipose

secretes

significantly

more

MCP-1.

Additionally,

macrophage accumulation was greater in the abdominal region of AngII-infused
mice compared to saline-infused mice and the number of recruited macrophages
to white adipose tissue was greater in mice that did develop AAAs compared to
those that did not.

These data suggest that in obese mice, AngII initiates

macrophage infiltration into peri-aortic adipose surrounding regions associated
with AAA formation. It is unclear, however, whether or not these effects are due
to direct action of AngII at the adipocyte AT1aR.
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Table 1.1 Summary of studies investigating the effects of AngII on adipocyte differentiation in vitro.
Publication

Adipocyte Effect of AngII
source
treatment
Ob1771
Pro-adipogenic
(mouse)

Measurements Receptors Antagonist
used
GPDH activity
AT2R
PD123177

3T3-L1
(mouse)
Human
preadip.

Pro-adipogenic

TG, FAS and
GPDH activity
Cyclin D
expression

AT2R*

P-186

AT1R

Losartan

Human
preadip.
Rat
preadip.

Anti-adipogenic

GPDH activity

N/A

None

Pro-adipogenic

Number of
GPDH-lipid
positive cells

N/A

N/A

Janke 2002

Human
preadip.

Anti-adipogenic

Lipid content

AT1R

Irbesartan

Matsushita
2006
Brucher
2007

Human
MSCs
Human
preadip.

Anti-adipogenic
Pro-adipogenic
Anti-adipogenic

PPARγ, FAS,
Adiponectin
GPDH activity

AT2R
AT1R
AT1R

PD123310
Valsartan
Losartan

Darimont
1994

Jones 1997
Crandall
1999
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Schling 2001
Saint-Marc
2001

Pro-adipogenic

Additional information
AngII elicits prostacyclin from
mature adipocytes to promote
differentiation of
preadipocytes
*Losartan had similar effects
to P-186
AngII increases cell cycle
progression; PD123319 had
no effect

AngII effects blocked by
aspirin and restored by
additional prostacyclin
treatment
PD123319 had no effect;
neither antagonist was used in
combination with AngII
AngII+PD restored adipogenic
markers to level of vehicle
Anti-adipogenic effect greater
in preadipocytes from obese s

Table 1.1 (continued)
Publication
Saiki 2008
Sarzani 2008

Fuentes 2010
Hung 2011
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Adipocyte
source
3T3-L1
(mouse)
Human
preadip
and adip

Effect of AngII
treatment
Anti-adipogenic

Measurements Receptors
PPARγ

AT1aR

Antagonist
used
Valsartan

Pro-adipogenic

Cell number

AT1R

Valsartan

Human
preadip.
3T3-L1
(mouse)

Anti-adipogenic

GPDH activity,
PPARγ
Lipid content

N/A

N/A

Both

Losartan
PD123319

N/A
(Endogenous)

Additional information
AngII also transiently increase
LPL activity
Cell number of mature and
differentiated preadipocytes
were measured in response to
AngII
Mechanism involves ERK1/2
activation
Losartan and PD reduced lipid
content to the same extent

Table 1.1 Summary of genetic ablation models of RAS components reporting body weight regulation.
Model

Massiera 2001

AGT-/-

Takahashi 2007

Renin (Ren1c-/-)

Jayasooriya 2008
Kouyama 2005

ACE-/AT1aR-/-

Yamamoto 2011

AT1aR-/-

Daugherty 2004
Tomono 2008
Yvan-Charvet
2005
Iwai 2009

AT1aR-/- x LDLR-/AT1aR-/- x ApoE-/AT2R-/-
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Publication

AT2R-/- x ApoE-/-

Diet
(weeks; beyond
weaning)
Chow
High fat
Chow (8-20)
Western (8-32)
Chow
Chow (8)
High fat (8)
Chow (12)
High fat (6)
Western (12)
Chow (20)
Low fat (12)
High fat (12)
Chow (24)
High Cholesterol (4)

Effect on body
weight

Effect on fat
mass

Effect on adipocyte
size

Reduced
Reduced
Reduced
Reduced
Reduced
No difference
Reduced
Increased
No difference
No difference
Increased
No difference
Reduced
No difference
No difference

Reduced
Reduced

N/A

Reduced
Reduced
No difference
Reduced
Increased
N/A
N/A
Reduced
No difference
Reduced
No difference
Increased

Reduced
N/A
No difference
Reduced
Increased
N/A
N/A
Reduced
Reduced
Reduced
No difference
Increased

Table 1.2 Criteria for diagnosis of the metabolic syndrome from IDF and AHA/NHLBI Joint Scientific Statement
Defining parameter
Elevated waist circumference

Requisite Levels
Non-Europeans: men ≥ 94 cm; women ≥ 80 cm
European origin: men ≥ 102 cm; women ≥ 88 cm
≥ 130/≥85
≥ 110
≥ 150

Elevated blood pressure*, mmHg
Elevated fasting blood glucose*, mg/dL
Elevated triglycerides*, mg/dL
Reduced HDL cholesterol*, mg/dL
Men
<40
Women
<50
IDF, International Diabetes Federation; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute.
*Drug treatment for indicated parameter is an alternate indicator.
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Figure 1.1 The renin-angiotensin system. AngII is formed from subsequent cleavage of angiotensinogen by renin and
ACE. AngII can act through two receptors, AT1R or AT2R, while smaller fragments such as AngIV or Ang(1-7) can act
through IRAP or the mas receptor, respectively.

Figure 1.2 Structure of AngII and the AT1R. A, The linear amino acid
structure of AngII. Boxed residues are involved in AT1R activation. B,
Schematic of AT1R (adapted from de Gasparo, 2000). Labeled open
circles are conserved residues, closed circles are involved in binding
AngII, and the circled amino acids (298-302) are involved in G-protein
activation. Receptor activation requires interactions between aromatic
Tyr and Phe residues of AngII and the Asn111 and His256 residues within
the transmembrane binding pocket of the AT1R.
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Figure 1.3 AT1R signaling pathways. A, G-protein dependent pathways, adapted from Dinh, et al. 2001. B, Gprotein independent pathways, from Hunyady, et al. 2006.
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Figure 1.4 Regulation of adipocyte differentiation. Factors involved in the commitment of MSCs to the adipocyte
lineage and the terminal differentiation of preadipocytes to mature adipocytes are shown; from Cristancho and Lazar
2011.

STATEMENT OF THE PROBLEM
The metabolic syndrome is a collection of risk factors that elevate an
individual’s risk for cardiovascular disease (Table1.3). Obesity is a central
component of the metabolic syndrome as well as an independent risk factor for
cardiovascular disease. Understanding how obesity changes normal adipocyte
physiology represents a major focus of current research aiming to ameliorate the
burden of obesity-associated disease. Adipocytes express all major components
of the renin-angiotensin system and are capable of both producing and
responding to AngII, though the functional purpose of this system in adipose
tissue is unclear. Adipose tissue is both a lipid storage and endocrine organ and
AngII could potentially modulate several of its functions, such as regulation of
adipogenesis, lipogenesis, lipolysis, insulin sensitivity, adipokine secretion, and
production of other RAS components.
Investigations into the effects of AngII on adipocyte differentiation have
yielded controversial results, leaving unanswered questions regarding whether
AngII affects adipocyte differentiation and through which receptor subtype (Table
1.1). Further studies into the metabolic effects of AngII in vivo using murine
models of whole-body angiotensinogen, renin, or ACE deficiency reveal that mice
with reduced capacity to synthesize AngII exhibit protection from diet-induced
obesity, improved glucose tolerance, and improved blood pressure when fed a
high fat diet. Similar results were obtained from studies of AT1aR- or AT2Rdeficient mice; however conflicting data have been reported. Paradoxically,
chronic infusion of AngII into mice results in reduced body weight and adiposity,
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similar to mice lacking major RAS components. In these studies, the
mechanisms and tissues responsible for the observed effects remain unknown.
AngII also promotes vascular disease through the AT1aR, as mice
deficient in this receptor are protected from hypercholesterolemia-induced
atherosclerosis and AngII-induced abdominal aortic aneurysms (AAAs). Similar
to the metabolic effects of AngII, however, it is unclear which tissues or cell types
participate in these effects. Obesity is a well-established risk factor for
cardiovascular disease and there is accumulating evidence for direct
contributions of adipose tissue, specifically adipose surrounding blood vessels, in
the development of these diseases. Our lab has demonstrated that obesity not
only promotes AngII-induced AAA formation, but abdominal peri-aortic adipose
tissue from the region susceptible to aneurysm formation secretes higher levels
of chemokines compared to non-aneurysmal thoracic regions, implying there
may be a direct effect of AngII on adipocytes to enhance AAA development.
The impact of adipocyte AT1aR activation on adipose tissue functions
could have significant health consequences, especially in the context of obesity
and its contribution to cardiovascular risk. The models used to study this
receptor, however, fall short of identifying cell-specific mechanisms for the
observed effects of AngII. To gain a better understanding of the physiologic and
pathologic effects of AngII on adipocytes and their contributions to obesity and
vascular disease, we created a model of adipocyte-AT1aR deficiency using the
Cre/LoxP system. The overall hypothesis of this dissertation is that adipocyte
AT1aRs mediate the development, function, and inflammatory profile of
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adipocytes and thus contribute to the development of obesity-related disorders
and vascular diseases. The following specific aims were designed to test this
hypothesis:
Specific Aim 1: Determine the role of adipocyte AT1aRs on the development
and function of adipose tissue.
A. Determine the effect of adipocyte-AT1aR deficiency on parameters of
the metabolic syndrome in lean and obese mice.
B. Determine the effect of AngII and AT1aR deficiency on adipocyte
differentiation using both 3T3-L1 and isolated stromal vascular cells from
adipocyte-AT1aR deficient mice.
Specific Aim 2: Determine the role of the adipocyte AT1aR on the development
of vascular disease.
A. Define temporal effects of high fat versus high fat/cholesterol diets on
the systemic and adipose RAS in LDLR-/- mice.
B. Determine the effect of adipocyte-AT1aR deficiency on the
development of atherosclerosis in hypercholesterolemic LDLR-/- mice fed
Western diet for 3 months.
C. Determine the effect of adipocyte-AT1aR deficiency on atherosclerosis
and AAAs induced by AngII infusion.

Copyright © Kelly Anne Putnam 2012
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SECTION II. SPECIFIC AIM 1
Determine the role of the adipocyte AT1aR on the development and function of
adipose tissue.
2.1 Summary
Adipocytes express angiotensin receptors, but the direct effects of
angiotensin II (AngII) stimulating this cell type remain unclear. Adipocytes
express angiotensin type 1a (AT1aR) and angiotensin type 2 receptors (AT2R),
both of which have been implicated in obesity. In this study, we determined the
effects of adipocyte AT1aR deficiency on adipocyte differentiation and the
development of obesity in mice fed standard mouse diet, low (LF) or high fat (HF)
diets. Mice expressing Cre recombinase under the control of the aP2 promoter
were bred with AT1aR floxed mice to generate mice with adipocyte AT1aR
deficiency (AT1aRaP2). AT1aR mRNA abundance was reduced significantly in
both white and brown adipose tissue from AT1aRaP2 mice compared to nontransgenic littermates (AT1aRfl/fl). In mice fed standard mouse diet, there was no
significant effect of adipocyte AT1aR deficiency on body weight, fat mass, or
glucose tolerance in 12 month old mice. To stress the system, mice of each
genotype were infused with saline or AngII for one month, after which modest
adipocyte hypertrophy was observed in saline-infused AT1aRaP2 mice and this
effect was significantly more pronounced in AngII-infused mice. To define the
effect of adipocyte AT1aR on the development of obesity, mice of each genotype
were fed LF or HF diets for 16 weeks. The mRNA abundance of other AngII
receptors, AT2R or angiotensin type 1b (AT1bR), were unaffected by deficiency
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of adipocyte AT1aRs. Additionally, angiotensinogen mRNA abundance in
adipose tissue was not significantly affected by adipocyte AT1aR deficiency.
Adipocyte AT1aR deficiency did not influence body weight, glucose tolerance, or
blood pressure in mice fed either LF or HF diets. However, LF-fed AT1aRaP2
mice exhibited striking adipocyte hypertrophy even though total fat mass was not
different between genotypes.

Stromal vascular cells from AT1aRaP2 mice

differentiated to a lesser extent to adipocytes compared to controls. Conversely,
incubation of 3T3-L1 adipocytes with AngII increased Oil red O (ORO) staining
and promoted mRNA abundance of PPARγ that was antagonized by losartan.
These results suggest that reductions in adipocyte differentiation in LF-fed
AT1aRaP2 mice resulted in increased lipid storage and hypertrophy of remaining
adipocytes. These results demonstrate that AngII regulates adipocyte
differentiation and morphology through the adipocyte AT1aR in lean mice.
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2.2 Introduction
The renin-angiotensin system (RAS) has well-established roles in fluid
homeostasis, blood pressure regulation, and the development of various forms of
cardiovascular diseases. Several cell types express components of the RAS
(16) allowing for angiotensin II (AngII) to elicit endocrine, autocrine, and/or
paracrine effects. Adipocytes express angiotensin receptors, with differences in
angiotensin receptor subtype expression depending on the species and source of
adipose tissue (44, 76, 297). In rodents, angiotensin type 1a receptors (AT1aR)
and angiotensin type 2 receptors (AT2R) have been localized to adipocytes (59,
61), while angiotensin type 1b receptors (AT1bR) are not readily detectable in
murine adipose tissue (36). The functional and/or pathophysiological role of
angiotensin receptor subtypes in adipocytes is unclear.
One possible role of angiotensin receptors on adipocytes may be to
regulate the production of angiotensinogen (AGT) from adipocytes, which are an
important extrahepatic source of circulating AGT (21, 160-161). Increased AGT
mRNA abundance in adipose tissue of AT2R deficient mice was reduced by an
AT1R-antagonist, suggesting that AngII upregulates AGT expression through the
AT1aR (154). Furthermore, AngII infusion dramatically increased AGT mRNA
levels specifically in adipose tissue and not liver (154). It remains to be
determined whether these results are due to direct effects of AngII at adipocyte
AT1aRs or through indirect effects at other cell types.
Regulation of body weight through changes in fat mass represents
another role of AngII, possibly through adipocyte receptors. Genetic ablation of
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RAS components including angiotensinogen, renin, angiotensin converting
enzyme (ACE), and AT1aR in mice results in reduced body weight due to
reductions in fat mass when mice are fed standard or high fat (HF) diets (125,
144, 161, 253), although there are contrary data (65, 154). Even more
perplexing, infusion of high doses of AngII can also result in weight loss and
reduced adiposity (34, 37, 47, 68), making it difficult to define the role of AngII in
the regulation of adipocyte growth and/or differentiation. These apparent
contradictions have yet to be resolved and are complicated by direct versus
indirect effects of AngII on adipose growth and development.
In studies aimed at examining direct effects of AngII to regulate adipocyte
differentiation using clonal cell lines or ex vivo differentiation of preadipocytes,
conflicting results have also been obtained. Several studies indicate that AngII
enhances adipocyte differentiation and lipid accumulation (61, 130, 221), while
others suggest that AngII inhibits adipocyte differentiation (85, 122, 220, 229).
There are also conflicting reports regarding which of the AngII receptors are
responsible for these effects, as investigators have reported that AngII stimulates
adipogenesis through the AT1R or AT2R (61), while other studies have reported
that AngII inhibits adipocyte differentiation (122). The use of AT1R antagonists
with AT1R-independent effects on adipocyte differentiation (i.e., activation of
peroxisome proliferator activated-receptor γ, PPARγ (123, 231)) complicates
interpretation of results from these studies.
Based on results from mouse models demonstrating that whole body
deficiency of components of the RAS reduces body weight and fat mass, we
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hypothesized that AngII promotes differentiation through direct effects at
adipocyte AT1aR, which may have therapeutic implications in the development
and/or treatment of obesity. To test this hypothesis, we generated mice with
adipocyte deficiency of AT1aR. In HF-fed mice, deficiency of AT1aR in
adipocytes had no effect on the development of obesity, glucose intolerance, and
obesity-induced hypertension. Notably, LF-fed mice lacking AT1aR in adipocytes
exhibited pronounced adipocyte hypertrophy, and stromal vascular cells (SVC)
isolated from mice with adipocyte AT1aR deficiency exhibited reduced capacity
to differentiate to adipocytes. These results suggest that AngII promotes
adipocyte differentiation through direct effects at adipocyte AT1aR in lean mice.
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2.3 Materials and Methods
2.3.1 Mice and diets
All experiments were conducted according to National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the
University of Kentucky Institutional Animal Care and Use Committee. AT1aR
floxed (AT1aRfl/fl) mice (212) were crossed initially to FLPe mice (B6.SJLTg(ACTFLPe)9205Dym/J, The Jackson Laboratory, Bar Harbor, ME) to remove
the neocassette and subsequently female AT1aRfl/fl mice were bred to
hemizygous transgenic male mice of Cre mice under control of an
aP2/promoter/enhancer.Cg-Tg (Fabp4-cre 1Rev/J; The Jackson Laboratory, Bar
Harbor, ME; Figure 2.1A). For all studies, male and female AT1aRfl/fl littermates
were used for comparison to mice with adipocyte AT1aR deficiency. Male mice
of each genotype were fed standard murine diet (18% kcal from fat; Harlan
Laboratories, Inc., Indianapolis, IN; Table 2.1) ad libitum through 12 months of
age and subsequently infused with either saline or AngII for 1 month. In separate
studies, male mice (8-10 weeks of age) of each genotype were fed either LF
(10% kcal as fat; D12450B; Research Diets, New Brunswick, NJ) or HF diets
(60% kcal as fat; D12492; Research Diets) ad libitum for 16 weeks with free
access to water. AT1aRaP2 mice were bred to ROSA26 mice (B6.129S4Gt(ROSA)26Sor<tm1Sor>/J, The Jackson Laboratory, Bar Harbor, ME) and βgalactosidase activity was measured to confirm lineage expression of Cre
recombinase in adipose tissue. Briefly, adipose tissues collected from aP2-Cre
null (Cre 0/0) and aP2-Cre positive (Cre+/0) AT1aRfl/+ mice heterozygous for the
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ROSA26 allele were sectioned and stained overnight with X-gal. Blue staining
indicated successful removal of a stop codon from the β-galactosidase gene by
Cre recombinase.
2.3.2 In vivo measurements
2.3.2.1 Standard murine diet with AngII infusion study
For mice fed standard mouse diet, body weights were recorded every
other week beginning at 6 months of age. Body composition was measured at 6,
9, 12, and 13 months of age. Glucose tolerance test was performed as
described above at 12 months of age. At 13 months of age, osmotic mini-pumps
(Model 2004, DURECT Corporation, Cupertino, CA) filled with either saline or
AngII (delivered at 1,000 ng/kg/min; Sigma, St. Louis, MO) were implanted
subcutaneously under isoflurane anesthesia. Mice were sacrificed at the end of
the 28-day infusion after a 4-hour fast. Blood pressure was measured by tail-cuff
(Visitech Systems, Inc., Apex, NC) prior to and 3 weeks after pump implantation.
2.3.2.2 LF and HF diets study
Body weights were recorded weekly for all mice. The body composition of
a subset of mice was analyzed by NMR spectroscopy (EchoMRI®) before mice
began the LF or HF diets and after 14 weeks on diet. Glucose tolerance tests
were performed after 8 and 15 weeks on diet. Mice were fasted 6 hours and
blood glucose measurements were measured at 0 min (before injection of
glucose solution) and at 15, 30, 60, and 120 minutes after i.p. injection of glucose
(1 g/kg body weight). After 14 weeks on diet, insulin tolerance tests were
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performed after a 4-hour fast. Insulin was administered at a dose of 0.5 U/kg
body weight via i.p. injection and blood glucose was measured at 0 min (before
injection of insulin) and at 30, 60, and 120 minutes after insulin injection. Blood
pressure was measured by telemetry for 3-days. After 15 weeks on diet,
telemetry implants (model TA11PA-C10, Data Sciences International, St. Paul,
MN) were surgically inserted as described previously (100). After 16 weeks on
diet, baseline blood pressures were recorded for 3 consecutive day and night
periods. Mice were excluded if their mean pulse pressure was below 17 mmHg,
as an indication of a poor signal from the telemeter to the receiver.
2.3.3 Plasma measurements
Mice were terminated after a 4 hour fast. Plasma renin concentrations
were measured by incubating plasma (8 µl) with exogenous angiotensinogen (25
nM) in the presence of ACE inhibitors and then angiotensin I (AngI) was
quantified by radioimmunoassay (DiaSorin, Via Crescentino, Italy). Plasma
insulin concentrations were quantified with the Ultra Sensitive Mouse Insulin
ELISA kit (Crystal Chem, Downers Grove, IL) and plasma leptin concentrations
were quantified with a Mouse Leptin ELISA kit (Millipore). Non-esterified fatty
acids (NEFAs) were quantified with the NEFA-HR(2) kit (Wako Diagnostics,
Richmond, VA). Plasma AGT concentrations were determined with the Mouse
Total Angiotensinogen Assay Kit (Immuno-Biological Laboratories Co., Ltd.,
Japan).
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2.3.4 Quantification of mRNA abundance
To quantify mRNA abundance, RNA was isolated using the SV Total RNA
Isolation System (Promega, Madison, WI). Reverse transcription was performed
on RNA (0.4 µg) using qScript cDNA SuperMix as per manufacturer’s instructions
(Quanta Biosciences, Gaithersburg, MD). Real-time PCR was performed with
PerfeCTa SYBR Green FastMix for iQ on 2ng of cDNA template (Quanta
Biosciences, Gaithersburg, MD). A standard curve was generated from a series
of ten-fold dilutions of cDNA with each real-time PCR plate and this was used to
extrapolate the relative starting quantity of mRNA for the gene of interest from
the given Ct values. Data are expressed as the ratio of the gene of interest
starting quantity to that of 18S.
2.3.5 Differentiation of preadipocytes from stromal vascular cells (SVC).
Subcutaneous adipose tissue was dissected from the inguinal region,
minced, and incubated in Basal Medium (OM-BM, Zenbio, Research Triangle
Park, NC) supplemented with collagenase (1 mg/mL) and
penicillin/streptomyocin mixture (5%) for at least 1 hour with shaking at 37 ⁰C as
described previously (215). Two days after cells had achieved 100% confluency,
media were changed to Differentiation Medium (OM-DM, Zenbio, Research
Triangle Park, NC) and replaced every other day for 8 days. Cells were either
harvested for RNA using TRIzol or fixed for Oil Red O (ORO) staining. For ORO
measurements, cells were fixed in formalin (10%) and stained in filtered ORO
(0.3%) solution for 30 minutes at room temperature. For quantification,
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isopropanol (1 ml) was added to the plates to extract ORO stain, this solution
was transferred to a microtiter plate, and absorbance was measured at 510 nm.
2.3.6 3T3-L1 adipocytes
3T3-L1 adipocytes were obtained from American Type Culture Collection
(Manassas, VA) and maintained in DMEM containing FBS (10%) and
penicillin/streptomyocin mixture (5%). Two days after cells were100% confluent,
differentiation of preadipocytes was initiated by administration of a cocktail
containing insulin (0.1 µM, Sigma-Aldrich, St. Louis, MO), dexamethasone (1 µM;
Sigma-Aldrich, St. Louis, MO), and isobutyl methyl xanthine (0.5 mM; SigmaAldrich, St. Louis, MO). Incubation with AngII (1 µM, Sigma-Aldrich, St. Louis,
MO) or losartan (1 µM) was performed with fresh media containing drugs
replaced every other day. After 6 days of differentiation cells were harvested for
RNA isolation using TRIzol reagent (Invitrogen, Carlsbad, CA) or for
quantification of ORO staining as described above.
2.3.7 Statistical analyses
Data were analyzed by ANOVA for comparisons between the 4
diet/genotype groups, as appropriate, using the Holm Sidak test for post-hoc
analysis. When time was an additional variable, data were analyzed by repeated
measures ANOVA. Data are represented as mean ± SEM. If normality or equal
variance tests failed, simple transforms were performed or the non-parametric
Kruskal-Wallis test was used with Dunn’s post-hoc analysis. Statistical
significance was defined as P<0.05.
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2.4 Results
2.4.1 Generation and characterization of mice with adipocyte AT1aR
deficiency
To confirm effective and specific deletion of exon 3 of AT1aR in
adipocytes, AT1aR mRNA abundance was quantified in adipose tissues, liver,
brain, heart, and kidney from mice fed standard laboratory diet (2 months of age).
AT1aR mRNA abundances were not significantly different in liver, kidney, or
brains from AT1aRfl/fl compared to AT1aRaP2 mice (Figure 2.1B). In heart,
AT1aR mRNA abundance was reduced modestly, but significantly, in AT1aRaP2
compared to AT1aRfl/fl mice. In interscapular brown (BAT) and epididymal white
(WAT) adipose tissue, AT1aR mRNA abundance was decreased significantly in
AT1aRaP2 compared to AT1aRfl/fl mice. Moreover, positive β-galactosidase
staining was present in subcutaneous white and interscapular brown adipose
tissues of Cre +/0 mice (Figure 2.1C).
Deficiency of AT1aR in adipocytes had no significant effect on body
weight (Figure 2.2A), body composition (Figure 2.2B), or glucose tolerance
(Figure 2.2C), quantified prior to infusions of saline or AngII in AT1aRfl/fl and
AT1aRaP2 mice. To stress the system, mice of each genotype were infused with
saline or AngII for 1 month. Systolic blood pressure increased significantly in
AngII-infused mice of each genotype, and was not significantly different between
genotypes (Table 2.2). As anticipated in response to infusion of AngII, plasma
renin concentrations decreased significantly in AngII-infused mice compared to
saline-infused mice, with no differences between genotypes (Table 2.2). Infusion
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of AngII had no significant effect on plasma NEFA concentrations, which were
not significantly different between genotypes (Table 2.2). The mean adipocyte
size in AT1aRaP2 mice infused with saline (3890 ± 157 µm2) was increased
modestly, but not significantly, compared to AT1aRfl/fl mice (3365 ± 117 µm2; P =
0.052, Figure 2.3G). Infusions of AngII resulted in a modest reduction in body
weight and fat mass in mice of each genotype (Figure 2.3A,B), with no significant
differences between genotypes. Interestingly, AngII infusion resulted in a striking
reduction in adipocyte size in AT1aRfl/fl mice (2167 ± 209 µm2; P <0.001)
compared to saline (Figure 2.3D versus 2.3C), but this effect was not apparent in
AT1aRaP2 mice (3514 ± 183 µm2; Figure 2.3D). However, the increased
adipocyte size in AngII-infused AT1aRaP2 mice compared to AngII-infused
AT1aRfl/fl controls (P < 0.001) was not associated with any differences in body
weight, fat mass, or plasma NEFA levels (Table 2.2).
2.4.2 Adipocyte-AT1aR deficiency had no effect on the development of obesity
or obesity-associated parameters
To define effects of adipocyte AT1aR deficiency on development of
obesity, mice of each genotype were fed a LF or HF diet for 16 weeks. HF-fed
mice of each genotype had significantly increased body weight and fat mass
compared to LF-fed controls (Figure 2.4A, B). However, adipocyte AT1aR
deficiency had no significant effect on body weight (Figure 2.4A) or fat/lean mass
(Figure 2.4B) in either LF or HF-fed mice. While the mass of retroperitoneal
(RPF) and epididymal (EF) adipose tissues were significantly increased by HF
feeding, there was no significant effect of genotype in either diet group (Table
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2.3). Glucose tolerance was significantly impaired in HF-fed mice of each
genotype compared to LF-fed controls (Figure 2.4C,D). However, adipocyte
AT1aR deficiency had no significant effect on glucose tolerance in either LF or
HF-fed mice. Similarly, while HF feeding significantly impaired insulin tolerance
tests in both genotypes, there was no significant difference in insulin tolerance
between LF or HF AT1aRaP2 mice compared to AT1aRfl/fl controls on respective
diets (Figure 2.4E). Plasma insulin and leptin concentrations were increased
significantly by HF-feeding in mice of each genotype, but there were no
significant differences between genotypes in either diet group (Table 2.3).
Plasma concentrations of non-esterified fatty acids (NEFAs) were not
significantly influenced by diet or genotype (Table 2.3).
Systolic blood pressures (SBPs) during the day and night cycle were
significantly increased in HF-fed mice of each genotype compared to LF-fed
controls (Figure 2.4F; P < 0.05). However, deficiency of AT1aR in adipocytes
had no significant effect on SBP in either LF or HF-fed AT1aRaP2 mice compared
to AT1aRfl/fl controls.
2.4.3 Adipocyte-AT1aR deficiency resulted in striking adipocyte hypertrophy in
lean mice.
Since adipocytes also express AT2Rs, which have been proposed to
contribute to obesity development in mice (289), we quantified mRNA abundance
of AT2R and AT1bR in adipose tissue from mice of each genotype. In AT1aRfl/fl
controls, AT2R mRNA abundance was increased significantly in visceral adipose
tissue from HF-fed mice compared to LF-fed controls (Figure 2.5A). However,
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there was no significant effect of AT1aR deficiency in adipocytes on AT2R mRNA
abundance in either visceral or subcutaneous adipose tissues of LF or HF-fed
mice. Similarly, AT1b mRNA abundance was not significantly influenced by diet
or genotype in visceral or subcutaneous adipose tissue (Figure 2.5B).
Quantification of AGT mRNA abundance in adipose depots revealed that
AGT expression was suppressed by HF-feeding in both visceral and
subcutaneous adipose depots (Figure 2.6A; P < 0.05), and adipocyte-AT1aR
deficiency had no effect on AGT expression in liver or adipose. Similarly, there
were no differences between genotypes in plasma AGT concentrations, although
HF diet increased plasma AGT (Figure 2.6B; P < 0.05).
We quantified adipose morphology in LF or HF-fed mice of each
genotype. In visceral retroperitoneal adipose tissue from LF-fed mice, adipocyte
AT1aR deficiency resulted in a greater number of large adipocytes (Figure 2.7AE). Mean adipocyte size in LF-fed AT1aRaP2 mice (2925 ± 361 µm2) was
increased significantly compared to adipocyte size in AT1aRfl/fl controls (1328 ±
146 µm2, P < 0.05; Figure 2.7E). Increases in adipocyte size in LF-fed AT1aRaP2
mice resulted in a significant reduction in the number of adipocytes within a
measurement frame compared to cell numbers in sections from LF-fed AT1aRfl/fl
controls (Figure 2.7F). With HF feeding, the number of large adipocytes
increased in both genotypes, but there were no significant differences between
genotypes (Figure 2.7A-E). Mean adipocyte size increased in HF-fed mice of
each genotype compared to LF-fed controls (HF, AT1aRfl/fl, 2923 ± 447 µm2;
AT1aRaP2, 3407 ± 432 µm2; P < 0.05, Figure 2.7E), but the number of adipocytes
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within a measurement frame was not different between genotypes (Figure 2.7F).
Notably, the size of adipocytes from LF-fed AT1aRaP2 mice was similar to
adipocyte sizes in HF-fed AT1aRfl/fl controls. However, despite the increase in
adipocyte size, adipose tissue mass was not significantly increased in LF-fed
AT1aRaP2 mice compared to AT1aRfl/fl controls (Table 2.3).
2.4.4 Deficiency of AT1aR in adipocytes decreased differentiation of SVCs
to adipocytes, while AngII promoted differentiation of 3T3-L1 adipocytes
Increases in size of adipocytes from LF-fed mice with adipocyte AT1aR
deficiency could result from reductions in lipolysis, alterations in lipid synthesis
and/or uptake, or from decreased capacity of preadipocytes to differentiate to
adipocytes. Plasma NEFA were not different between LF-fed mice of each
genotype, suggesting that lipolysis was not influenced by adipocyte AT1aR
deficiency. We examined the ability of preadipocytes within SVCs isolated from
mice of each genotype to differentiate into mature adipocytes. AT1aR mRNA
abundance was significantly decreased in adipocytes (day 8) differentiated from
SVCs of AT1aRaP2 mice compared to AT1aRfl/fl controls (AT1aRfl/fl, 0.30 ± 0.02;
AT1aRaP2, 0.16 ± 0.01 AT1aR/18S RNA ratio; P < 0.001). Deficiency of AT1aR
resulted in significantly reduced ORO staining on day 8 of differentiation
compared to SVCs differentiated from AT1aRfl/fl controls (Figure 2.8A; P <
0.0001). In addition, mRNA abundance of PPARγ was significantly decreased in
adipocytes differentiated from AT1aRaP2 mice compared to AT1aRfl/fl controls
(Figure 2.8B; P < 0.05). Reductions in ORO staining occurred in the absence of
changes in mRNA abundance of either fatty acid synthase or CD36 (Figure
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2.8C,D, respectively). Conversely, incubation of 3T3-L1 preadipocytes with AngII
throughout the differentiation protocol significantly increased ORO staining and
mRNA abundance of PPARγ in mature adipocytes (Figure 2.8E,F, respectively;
P < 0.05). AngII-mediated increases in PPARγ mRNA abundance were
abolished when 3T3-L1 adipocytes were incubated with the AT1R antagonist,
losartan (Figure 2.8F). However, incubation of preadipocytes with losartan in the
absence of AngII had no significant effect on PPARγ mRNA abundance in
differentiated adipocytes.
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2.5 Discussion
Results from this study demonstrate that adipocyte AT1aR deficiency
promotes the development of adipocyte hypertrophy in mice fed either standard
mouse diet and infused with AngII or in mice fed a LF diet. Surprisingly, the
phenotype of adipocyte AT1aR deficiency to increase adipocyte size was only
apparent in lean mice (LF-fed or AngII-infused). The size of adipocytes in LF-fed
mice AT1aRaP2 mice was similar to the size of adipocytes in non-transgenic
littermate mice fed a HF diet. However, despite increases in adipocyte size in
AT1aRaP2 mice, fat mass was similar in mice of each genotype fed standard
mouse diet or the LF diet. Thus, adipocyte hypertrophy in lean AT1aRaP2 mice,
in the absence of increases in total adipose tissue mass, was insufficient to
promote differences in body weight, glucose tolerance or blood pressure.
Preadipocytes from adipocyte-AT1aR deficient mice demonstrated reduced
capacity to differentiate to adipocytes, suggesting that the increased adipocyte
size in lean AT1aRaP2 mice occurred as a consequence of increased lipid storage
in a reduced number of adipocytes. Conversely, incubation of 3T3-L1 adipocytes
with AngII promoted ORO staining and PPARγ expression in differentiating
adipocytes, supporting a role for AngII to promote adipocyte differentiation.
Surprisingly, the effects of adipocyte AT1aR deficiency to increase adipocyte cell
size in LF-fed mice were not observed when mice were fed a HF diet. These
results suggest that adipocyte AT1aR regulate adipocyte differentiation under
lean, but not obese conditions.
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Adipose tissue expresses several components of the RAS necessary to
produce and respond to AngII. Results from this study confirm previous reports
that murine adipocytes express both AT1aR and AT2R, with low levels of AT1bR
(36, 61). Adipocyte AT1Rs have been suggested to regulate expression of RAS
components in adipocytes, adipocyte differentiation or growth, or adipocyte
glucose uptake or metabolism (61, 133, 154). Murine models of global genetic
AT1aR deletion and systemic administration of angiotensin receptor blockers
(ARBs) to rodents have been previously used to study effects of this receptor on
the development of obesity (144, 175, 296). Specifically, whole body deficiency
of angiotensinogen, renin, or ACE in mice fed standard mouse diet resulted in
reduced body weight, fat mass, glucose intolerance, and decreased blood
pressure (125, 161, 253). In addition, whole body deficiency of angiotensinogen,
ACE, AT1aR or AT2R reduced the development of obesity in mice fed a HF diet
(144, 161, 206). Conversely, previous results from our laboratories
demonstrated that deficiency of AT1aR or AT2R in low density lipoprotein
receptor deficient mice fed a HF diet had no effect on body weight (65). These
conflicting data are confounded by an inability to define the cell type(s)
responsible for effects of whole body deficiency of individual RAS components.
To address the direct role of AngII effects at adipocyte AT1aR, we created mice
with deficiency of AT1aR in adipocytes, and demonstrate a lack of effect on body
weight or fat mass when mice are fed a LF or HF diet. These results
demonstrate that previously observed effects of whole body AT1aR deficiency to
decrease the development of obesity (144) result from reduced effects of AngII at
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other cell types. Additionally, it is possible that improvements in glucose
tolerance and blood pressure observed in mice with whole body AT1aR
deficiency (144) are secondary to the previously observed leaner phenotype of
these animals, as adipocyte AT1aR deficiency had no effect on these obesityassociated parameters.
Since whole body AT2R deficiency has also been reported to reduce the
development of obesity (289), albeit with conflicting results (65) a possible
explanation for the lack of effect of adipocyte-AT1aR deficiency on the
development of obesity may be compensation by this receptor in adipocytes. In
the present study, quantification of mRNA abundance of AT1bR and AT2R from
whole adipose tissue lysates did not reveal transcriptional upregulation of either
receptor to compensate for the loss of adipocyte AT1aRs. Thus, it is unlikely that
effects of adipocyte AT1aR deficiency were masked by compensation through
AngII effects at other receptor subtypes.
Adipose AGT production has been shown to be regulated by AngII
through the AT1aR (154); however, the results of this study demonstrate that
these effects are independent of direct actions at adipocyte AT1aRs. Consistent
with other reports, HF diet reduced AGT mRNA abundance in both visceral and
subcutaneous adipose tissues (191) while plasma AGT levels were actually
increased (287). This apparent discrepancy is likely due to increased overall
AGT production due to the dramatic increase in fat mass resulting from HF diet
despite downregulation of gene transcription (283). Increased production of AGT
by other tissues is also possible in the setting of obesity.
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A surprising finding from this study was that AT1aRaP2 mice have large
adipocytes when fed a LF diet or when fed standard diet and infused with AngII.
Quantification of mean adipocyte size indicated that the magnitude of adipocyte
hypertrophy in LF-fed AT1aRaP2 mice was similar to the hypertrophy observed in
HF-fed control mice. Also, AT1aRaP2 mice exhibited adipocyte hypertrophy
compared to AT1aRfl/fl controls when infused with AngII. It is unclear why
infusion of AngII was required to bring forth significant differences in adipocyte
size in chow-fed mice, though this is likely related to the modest weight loss
experienced by AngII-infused mice, suggesting the phenotypes of adipocyteAT1aR deficient mice are most prominent when mice are leaner.
Despite these striking increases in adipocyte size, there were no
differences in fat mass between genotypes on either chow or LF diets. The
finding of similar fat masses in lean mice of each genotype, despite marked
adipocyte hypertrophy in AT1aRaP2 mice, suggests that a smaller number of
adipocytes in LF AT1aRaP2 mice accumulated more lipid to maintain adipose
mass at a similar level between genotypes (13). In accordance with the lack of
an effect on fat mass, there was no evidence of glucose intolerance, and no
changes in plasma insulin or leptin concentrations in LF-fed AT1aRaP2 mice,
signifying that in lean mice adipocyte hypertrophy alone is insufficient to alter
levels of these proteins associated with an obese phenotype.
Adipocyte hypertrophy in lean mice with adipocyte AT1aR deficiency could
result from several mechanisms, including reduced lipolysis, reduced numbers of
adipocytes (with remaining adipocytes filling up with lipid), or increased lipid
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synthesis or uptake in resident adipocytes. Since plasma concentrations of
NEFA were not different in LF-fed mice of either genotype, lipolysis was most
likely not influenced by AT1aR deficiency in adipocytes. The literature on AngII
regulation of lipolysis is conflicting, with some reports demonstrating minimal
effects of AngII on adipose tissue lipolysis in humans (264), as compared to
reductions in lipolysis of human adipose tissue in response to AngII in normal
weight (31) and obese subjects (95). In this study, mRNA abundance of fatty
acid synthase and CD36 were not altered in AT1aR deficient adipocytes,
suggesting that reduced synthesis and/or uptake of lipids most likely did not
contribute to differences in Oil Red O staining. Others have reported that AngII
induces fatty acid synthase expression in 3T3-L1 adipocytes, however it was
unclear whether these effects were through AT1aR or AT2R (130) and little has
been reported regarding regulation of CD36 by AngII in adipocytes.
Since results did not support changes in lipid uptake, mobilization and/or
synthesis in adipose tissue from LF-fed mice with adipocyte AT1aR deficiency,
we focused on adipocyte differentiation as a potential mechanism contributing to
hypertrophy of remaining adipocytes. Indeed, preadipocytes isolated from mice
lacking adipocyte AT1aR differentiated ex vivo had reduced lipid accumulation
and PPARγ mRNA abundance, indicating a reduced capacity for differentiation.
Results from this study conflict with those of Kouyama, et al. who examined
mouse embryonic fibroblasts (MEFs) isolated from wild type and whole body
AT1aR deficient mice and found no difference in their ability to differentiate into
adipocytes (144). Differences between results from these studies may reflect the
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differences between culture systems (i.e., preadipocytes from the SVF compared
to MEFs). In addition, results from this study demonstrate that previously
observed protection against the development of obesity in whole body AT1aR
deficient mice occurred independent of adipocyte AT1aR.
Notably, we observed no differences in adipocyte morphology in HF-fed
AT1aRaP2 mice which may be due to the suppression of adipocyte differentiation
that other groups have found occurs in the setting of obesity or prolonged HF
feeding (101, 116, 127, 197), however conflicting reports highlight the complex
dynamics of adipocyte cell numbers and turnover in obesity (15, 222, 243).
Interestingly, some suggest that adipocyte hypertrophy in HF-fed humans and
rodents is a result of reduced adipogenesis and that the remaining cells
accumulate more lipid over time (13). Our results support this conclusion that
reduced adipocyte differentiation results in adipocyte differentiation in lean mice.
In HF-fed mice, however, the inhibition of adipocyte differentiation occurs as a
result of an inability to suppress canonical anti-adipogenic WNT signaling (101).
WNT signaling is an important determinant of mesenchymal stem cell
commitment to the adipocyte lineage and appears to precede the regulatory
effects of AngII on adipocyte differentiation since no changes in adipocyte size in
HF-fed AT1aRaP2 mice were observed.
Our results demonstrate that AngII promotes differentiation of murine 3T3L1 adipocytes in an AT1R-dependent manner. Several in vitro experiments
using adipocyte cell lines have implicated a role for AngII in lipid accumulation
and differentiation of adipocytes, with conflicting results. Initial studies from
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Darimont, et al. demonstrated that AngII promoted adipocyte differentiation of
Ob1771 mouse adipocytes by eliciting PGI2 from mature adipocytes via AT2Rs
(61). In another study, AngII increased glycerol-3-phosphate dehydrogenase
(GPDH)-positive, lipid-containing cells in mouse adipose tissue explants, though
the role of specific AngII receptors were not investigated (221). A pro-adipogenic
effect of AngII was confirmed in 3T3-L1 and human adipocyte primary cells
where AngII increased triglyceride content, fatty acid synthase activity, GPDH
activity, and lipid accumulation, though in these studies both AT1R and AT2R
antagonists abolished AngII-induced effects (114, 130). Other reports, however,
indicate that AngII decreased lipid content as well as PPARγ and fatty acid
synthase in 3T3-L1 and isolated human adipocytes (85, 122, 220). While
discrepancies in the literature may be due to the variety of culture systems,
sources of adipocytes, differentiation cocktails, and experiment durations used by
each group, this field of research is also complicated by the AT1R-independent
stimulation of PPARγ by some AT1R antagonists (22, 216, 231). For example,
Wistar Kyoto rats administered candesartan exhibited increased expression of
PPARγ expression in adipose tissue and consequently had a larger number of
small adipocytes (296). Similar results have been reported with telmisartan and
irbesartan (123, 175, 242). It would be interesting in future studies to examine
effects of AT1R antagonists with PPARγ-stimulating properties in AT1aR
deficient adipocytes to better define the AT1R-independent effect of this class of
compounds.
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In conclusion, adipocyte AT1aR deficiency had no effect on development
of obesity or obesity-induced hypertension and dysregulated glucose
homeostasis. However, in lean mice, deficiency of AT1aR in adipocytes
promoted striking adipocyte hypertrophy, without the negative consequences
typically associated with this phenotype. Mechanisms for effects of adipocyte
AT1aR deficiency include reductions in differentiation of preadipocytes to mature
adipocytes, resulting in increased lipid accumulation across a smaller number of
adipocytes in LF-fed mice. Conversely, AngII promoted the differentiation of
3T3-L1 adipocytes through an AT1R-dependent mechanism. These results
demonstrate that AngII acts at adipocyte AT1aR to regulate adipose tissue
growth in lean mice, which may have implications in diseases associated with
cachexia.
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Table 2.1 Composition of diets.
Standard chow

Low Fat

High Fat

Source

Harlan Teklad
Global 18% Protein
Rodent Diet, 2018

Research Diets,
Inc. D12450B

Research Diets,
Inc. D12492

Kcal/g

3.1

3.85

5.24

Protein (% of total
kcal)

24

20

20

Carbohydrate (% of
total kcal)

58

70

20

Fat (% of total kcal)

18

10

60

Fat sources

Soybean oil

Soybean oil (55%
of fat kcal), lard
(45% of fat kcal)

Lard (91% of fat
kcal), soybean oil
(9% of fat kcal)
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Table 2.2 Effects of adipocyte AT1aR deficiency on fat mass and plasma
measurements in mice fed standard murine diet.
Saline
AT1aRfl/fl

AngII
AT1aRaP2

AT1aRfl/fl

AT1aRaP2

EF mass (g)

1.68 ± 0.4

1.72 ± 0.4

1.25 ± 0.2

1.344 ± 0.1

RPF mass (g)

0.40 ± 0.08

0.48 ± 0.08

0.40 ± 0.07

0.48 ±0.04

Final systolic blood
pressure (mmHg)

105 ± 2

104 ± 0.9

126 ± 5*

123 ± 5*

Plasma renin
(AngI ng/mL)

2.00 ± 0.93

2.44 ± 0.70

0.084 ± 0.05*

0.30 ± 0.35*

Plasma NEFAs
(mEq/L)

0.036 ± 0.003

0.04 ± 0.005

0.041 ± 0.003

0.037 ± 0.002

Values are means ± SEM (n = 4-5 per group). Effect of AngII, *P < 0.05.

76

Table 2.3 Effects of adipocyte AT1aR deficiency on fat mass and plasma
measurements in LF- and HF-fed mice.
HF

LF
AT1aRfl/fl

AT1aRaP2

AT1aRfl/fl

AT1aRaP2

EF mass (g)

1.01 ± 0.18

1.07 ± 0.21

1.66 ± 0.07*

1.54 ± 0.06*

RPF mass (g)

0.40 ± 0.09

0.39 ± 0.08

1.46 ± 0.06*

1.46 ± 0.13*

Plasma leptin
(ng/mL)

11.8 ± 2.2

13.3 ± 2.8

56.0 ± 1.5*

49.5 ± 3.5*

Plasma insulin
(ng/mL)

0.34 ± 0.04

0.55 ± 0.26

1.06 ± 0.19*

1.96 ± 0.42*

Plasma NEFAs
(mEq/L)

1.38 ± 0.14

1.47 ±0.12

1.51 ± .21

1.40 ± 0.27

Animals were fasted for 4 hours prior to sacrifice. Values are means ± SEM (n
= 10-15 per group). Effect of diet, *P < 0.05.

77

A

B

AT1aRfl/fl
AT1aRaP2

AT1aR:18s

1.75

*

0.75

0.1

*

*

BAT

WAT

0.0
Liver

Kidney

Heart

Brain

C
Cre 0/0

Cre +/0
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Figure 2.1 Development of mice with adipocyte deficiency of
AT1aR. A, Mice with loxP sites flanking exon 3 of the AT1aR gene (a)
were bred to mice expressing flippase (FLP) which recognizes the FRT
sites to remove the neocassette (b). (c) AT1aRfl/fl mice were bred to
transgenic mice expressing Cre recombinase driven by the aP2 promoter
to generate adipocyte AT1aR deficient mice (AT1aRaP2) and nontransgenic littermates (AT1aRfl/fl). B, AT1aR adipocyte deficiency was
confirmed in brown (BAT) and white adipose tissues (WAT, respectively).
C, Cre recombinase activity was confirmed with X-Gal staining in BAT
and subcutaneous adipose of AT1aRaP2 bred to ROSA26 mice (Cre+/0)
but not in mice lacking Cre recombinase (Cre 0/0). Data are represented
as mean ± SEM from n = 8-10 mice/group. *, P < 0.05 compared to
AT1aRfl/fl.
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and decreased, respectively, at 12 months of age compared to 6 months of age,
*, P < 0.05. C, Glucose tolerance test performed at 12 months of age. Data are
represented as mean ± SEM from 4-5 mice/group.
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Figure 2.3 AngII infusion reduces adipocyte size in AT1aRfl/fl but not
AT1aRaP2 mice fed standard diet. A, AngII infusion for 4 weeks in mice fed
standard murine diet causes modest, but not significant, weight loss. B, Neither
AngII infusion nor adipocyte AT1aR deficiency affects % fat or lean mass in
aged mice. C, Frequency distribution of saline- and (D) AngII-infused mice. E,
Images of saline- and (F) AngII-infused H&E stained adipocytes (scale bar
represent 200µm). G, Saline-infused AT1aRaP2 mice exhibit modest adipocyte
hypertrophy (P = 0.052) and AngII infusion reduces adipocyte size in AT1aRfl/fl
mice (*, P < 0.001 effect of treatment; **, P < 0.001 effect of genotype). Data
are represented as mean ± SEM from 3-5 mice/ group.
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Figure 2.4 Deficiency of AT1aR in adipocytes had no effect on development
of obesity or obesity-associated glucose intolerance. A, Body weight over
15 weeks of LF or HF feeding in mice of each genotype. Beginning at week 3,
HF-fed mice of each genotype had significantly increased body weight compared
to LF-fed controls. B, Fat and lean mass (% body weight) of AT1aRfl/fl and
AT1aRaP2 mice fed LF or HF diets for 16 weeks. C, Blood glucose concentrations
at selected time points following a bolus of glucose (time 0) in AT1aRfl/fl and
AT1aRaP2 mice fed a LF or HF diet for 15 weeks. D, Area under the curve (AUC,
arbitrary units) quantification of blood glucose concentrations shown in C. Data
are represented as mean ± SEM from n = 9-12 mice/group. *P < 0.05 or **P <
0.001 compared to LF within genotype.
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Figure 2.5 Deficiency of AT1aR in adipocytes has no effect on mRNA
abundance of other angiotensin receptors in adipose tissues. mRNA
abundance of AT2R (A) and AT1bR (B) was quantified in visceral and
subcutaneous adipose tissues from LF and HF-fed AT1aRfl/fl and AT1aRaP2 mice.
Data are represented as mean ± SEM from n = 5-7 mice/group. *, P < 0.05
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85

A

3

#

#

# #

AT1aRfl/fl
AT1aRaP2

AGT:18s

2
1
0.15

* *

0.10

†

0.05

†

*,† *,†

0.00
LF

HF

Liver

LF

LF

HF

Visceral
adipose

HF

Subcutaneous
adipose

Angiotensinogen (pmol/L)

B
5000
4000

AT1aRfl/fl
AT1aRaP2

*

*

3000
2000
1000
0
LF

HF

Figure 2.6 HF diet suppresses adipose AGT mRNA abundance and
increases plasma AGT concentration. A, AGT mRNA abundance was
quantified in liver, visceral and subcutaneous adipose tissues (#, P < 0.05
compared to either adipose depot; *, P < 0.05 compared to LF within adipose
depot; †, P < 0.05 compared to visceral adipose or liver). B, Plasma AGT
concentrations (*, P < 0.05 effect of diet). Data are represented as mean ± SEM
from n = 4-10 mice/group.

86

B
80

Adipocyte size (µm2 )

C

70
00

60
00

Adipocyte size (µm2 )

D

E

F
AT1aRfl/fl
AT1aRaP2
**

250
Cell number
(per measurement frame)

4000
M ean adipocyte size (µm2 )

50
00

0

70
00

60
00

50
00

0

40
00

0
30
00

20

40
00

40

20

20
00

AT1aRaP2 HF

60

30
00

40

AT1aRfl/fl HF

20
00

AT1aRaP2 LF

60

# of cells

AT1aRfl/fl LF

0
10
00

# of cells

80

10
00

A

*

3000

2000

1000

AT1aRfl/fl
AT1aRaP2

200
**
150

*

100
50
0

0
LF

LF

HF

87

HF

Figure 2.7 Adipocyte AT1aR deficiency resulted in striking adipocyte
hypertrophy in LF-fed mice. Histograms of adipocyte number of selected
areas quantified in adipose tissue sections using image analysis software
(sections from n = 3 mice/group and 3 image fields per section) from LF (A) or
HF-fed mice (B). Representative images of H&E stained sections of
retroperitoneal visceral adipose tissue used for quantification of adipocyte sizes
from LF (C) or HF-fed mice (D) of each genotype. Scale bar in lower right
represents 200 µm. E, Quantification of mean adipocyte area. F, Quantification
of adipocyte number per measurement frame. Data are represented as mean ±
SEM from n = 9 mice/group. *P < 0.005 compared to LF within genotype. **P <
0.05 compared to AT1aRfl/fl within diet group.
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Figure 2.8 Deficiency of AT1aR reduced differentiation of SVC to
adipocytes while AngII promotes differentiation of 3T3-L1 adipocytes. A,
ORO staining (510 nm) of adipocytes differentiated from SVCs of AT1aRfl/fl and
AT1aRaP2 mice. Data are represented as mean ± SEM from n = 3-5
samples/genotype. PPARγ (B), fatty acid synthase (C), and CD36 (D) mRNA
abundance in adipocytes (day 8) differentiated from SVCs of AT1aRfl/fl and
AT1aRaP2 mice. Data are mean ± SEM from n = 8-11 samples/group. (E) ORO
staining of 3T3-L1 adipocytes differentiated in the absence (vehicle) or presence
of AngII (1 µM). F, PPARγ mRNA abundance in 3T3-L1 adipocytes differentiated
in the absence or presence of AngII, losartan, or AngII + losartan (1 µM of each
compound). Data are represented as mean ± SEM from n = 4-5 samples/group.
A-C: *, P < 0.05 compared to AT1aRfl/fl. F,G: *, P < 0.05 compared to vehicle;
**, P < 0.05 compared to AngII.
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SECTION III. SPECIFIC AIM 2
Determine the role of the adipocyte AT1aR on the development of
vascular diseases.
3.1 Summary
While obesity is a well-established risk factor for cardiovascular diseases,
few studies have investigated the possible involvement of adipose tissue
surrounding blood vessels in the progression of this disease. The amount of
epicardial or perivascular fat is positively correlated to the amount of
atherosclerotic lesion area in the underlying vessels and perivascular fat has
been shown to have a pro-inflammatory phenotype, though it remains unclear if
perivascular adipose inflammation plays a causative role in lesion formation.
AngII is known to promote various forms of vascular diseases, independent of
blood pressure increases, though the cell type through which AngII acts remains
unknown. We tested the hypothesis that AngII acts as a proinflammatory
stimulus through the adipocyte AT1aR, and deficiency of this receptor in
adipocytes is protective against the development of atherosclerosis and
abdominal aortic aneurysms (AAAs). To understand how hypercholesterolemia
affects the expression and production of RAS components, particularly in
adipose tissue, LDLR-/- mice were fed standard mouse diet (termed “chow”),
Western, or high fat (HF) diets for 1 to 3 months. Body weights of HF- and
Western-fed mice were significantly greater than those of chow-fed mice, though
only Western diet induced hypercholesterolemia and hypertriglyceridemia.
AT1aR mRNA abundance varied across adipose depots, but was markedly
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suppressed in both thoracic and abdominal peri-aortic fat (PAF) depots after 3
months of Western or HF diets. In Western diet-fed mice previously
demonstrated to exhibit an activated systemic renin-angiotensin system (RAS),
plasma renin concentrations (PRC) were increased, while HF-fed mice exhibited
elevations in plasma angiotensinogen (AGT) concentrations. AT1aRfl/fl x LDLR-/mice and AT1aRaP2 x LDLR-/- mice were fed Western diet for 3 months to
examine the role of endogenous AngII acting at the adipocyte AT1aR in the
development of atherosclerosis, though no differences between genotypes were
observed in this study. A model of AngII infusion known to augment
atherosclerosis and induce AAA formation in mice fed Western diet for 5 weeks
was used to determine the role of the adipocyte AT1aR in exogenous AngIIinduced vascular pathologies; however, there were no differences in lesion
formation or AAA development between genotypes. Previous studies revealed
that adipocyte-AT1aR deficiency resulted in adipocyte hypertrophy in lean but not
obese mice, and interestingly, modest adipocyte hypertrophy was also noted in
retroperitoneal adipose of AngII-infused AT1aRaP2 x LDLR-/- mice. These effects
were independent of adipose tissue lipolysis and similar to results in lean mice.
Results from these studies demonstrate that adipocyte-AT1aR deficiency does
not influence the development of atherosclerosis in LDLR-/- mice fed Western diet
chronically or infused with AngII for 1 month during diet feeding. Also, deficiency
of adipocyte AT1aRs did not alter the formation or severity of AngII-induced
AAAs. Adipocyte hypertrophy was modest in AT1aRaP2 x LDLR-/- mice compared
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to lean mice in other studies, suggesting that the effect of adipocyte-AT1aR
deficiency to reduce adipocyte differentiation is partially reduced by Western diet.
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3.2 Introduction
Heart disease and stroke are among the leading causes of death
worldwide with other forms of vascular disease not far behind (176).
Understanding the mechanisms behind the initiation and progression of these
diseases is essential for the development of effective therapeutic strategies.
Pharmacologic blockade of the RAS through ACE inhibitors and ARBs reduces
the risk of cardiovascular mortality (5), implying a causative role for AngII in these
diseases. Murine models of hypercholesterolemia have been shown to stimulate
the production of circulating angiotensin peptides and furthermore, infusion of
AngII into hypercholesterolemic mice promotes the formation of atherosclerotic
lesions (62) and induces aortic aneurysms (63). The exact mechanisms through
which AngII promotes these vascular diseases are still being elucidated.
Deletion of the AT1aR gene in LDLR-/- and ApoE-/- mice markedly reduces
atherosclerotic lesion area and attenuates the formation of abdominal aortic
aneurysms (AAAs) (65, 276). The AT2R, on the other hand, protects against
these pathologies (64, 112, 120), though these results are controversial (65).
Interestingly, although the AT1aR clearly has pathological effects, the cell type(s)
mediating the increases in atherosclerosis and AAAs remain elusive (49, 87, 138,
212).
Adipocytes are an understudied contributor to vascular disease, though
interest in perivascular adipose tissue has increased in the past few years (194,
251). Quantification of epicardial and perivascular adipose depots through
various imaging techniques has allowed several groups to establish significant
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positive correlations between the presence/amount of adipose tissue in
epicardial, pericardial, or perivascular depots and the presence/severity of
atherosclerotic lesions in corresponding blood vessels (56, 150, 158, 227, 285).
A functional paracrine relationship between perivascular adipose and the
inclusive vessel was first recognized with the discovery that perivascular adipose
modulates vessel contractility through the release of vasoactive signaling
molecules (151, 153, 240, 274). Furthermore, the proinflammatory phenotype of
perivascular compared to visceral or subcutaneous adipose depots (51, 103,
109) suggests the influence of perivascular adipose extends beyond modulation
of vessel contraction to impact the infiltration of immune cells to the vessel wall, a
critical component of both lesion and aneurysm formation. Indeed, adipose
transplant studies have provided direct evidence for the contribution of adipose
tissue to the development of atherosclerosis (188-189). A large clinical trial of
over 12,000 men has demonstrated an independent association between obesity
and AAA formation (93). Correspondingly, obesity promoted the development of
AngII-induced AAAs in normocholesterolemic mice fed a HF diet (203). Results
from this mouse model indicate perivascular adipose tissue surrounding the
abdominal region of aortas from obese mice secretes more chemokines than the
thoracic region and thus may contribute to the inflammation and formation of
aneurysms in this region (203). These studies suggest that AngII may act
directly on perivascular adipocytes through the AT1aR to promote the formation
of atherosclerotic lesions and AAAs. The following studies investigated the
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possible role of the adipocyte-AT1aR on the development of atherosclerosis and
AAA in hypercholesterolemic LDLR-/- mice.
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3.3 Materials and Methods
3.3.1 Mice and diets
All mice were fed respective diets ad libitum and given free access to
water. Mice were group-housed and exposed to 12 hours of light and dark each
day. Experimental protocols were approved by the University of Kentucky
Institutional Care and Use Committee.
LDLR-/- time course diet. Eight week old LDLR-/- (Stock #; Jackson
Laboratory, Bar Harbor, ME) were purchased and placed on either standard
mouse diet (termed “chow”), Western diet (D ; Teklad) comprised of 42% kcal as
fat and 0.15% cholesterol, or high fat (HF) diet (Research Diets) comprised of
60% kcal as fat (Table 3.1). Groups of mice were maintained on diet for either 1,
2, or 3 months (n = 8).
Diet-induced atherosclerosis. Mice with adipocyte-AT1aR deficiency
(AT1aRaP2) were bred to LDLR-/- mice to generate AT1aRaP2 x LDLR-/- and
AT1aRfl/fl x LDLR-/- mice. At 8-10 weeks of age, all mice were fed Western diet
for a total of 3 months.
AngII-induced AAA and atherosclerosis. AT1aRaP2 x LDLR-/- and AT1aRfl/fl
x LDLR-/- mice were fed Western diet for a total of 5 weeks beginning at 8-10
weeks of age. After the first week on diet, mice were implanted with Alzet 28-day
osomotic mini-pumps (Model 2004, DURECT Corporation, Cupertino, CA) filled
with either saline or AngII (Sigma, St. Louis, MO) delivered at a rate of 1,000
ng/kg/min. Mini-pumps were implanted subcutaneously under a low dose of
ketamine/xylazine anesthesia and bupivacaine was used as a local anesthetic
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over the stapled closure site. Anesthetized mice were exsanguinated at the end
of the 28-day infusion after a 4-hour fast for plasma and tissue harvest.
3.3.2 In vivo measurements
Body composition measurements were performed monthly using NMR
spectroscopy (EchoMRI). Blood pressure was measured non-invasively by the
tail-cuff method (Visitech Systems, Inc., Apex, NC). Blood pressure
measurements were performed at the end of each month during the LDLR-/- time
course diet study, during the week prior to and the third week during AngII
infusion in the AngII-induced AAA study. Preliminary measurements were taken
each day prior to data collection and the criteria for inclusion required at least 5
(out of 10) successful measurements per day with less than 30% standard
deviation. For the AngII infusion study, ultrasound images of the abdominal aorta
above the renal branches were obtained for quantification of lumen diameters at
day 0, 14, and 28 of AngII infusion (Vevo 2100, VisualSonics, Toronto, Canada).
3.3.3 Plasma and serum measurements
Plasma renin concentrations were measured by incubating plasma (8 µl)
with exogenous AGT (25 nM) in the presence of ACE inhibitors and then
angiotensin I (AngI) production was quantified by radioimmunoassay (DiaSorin,
Via Crescentino, Italy). Plasma AGT levels were measured with the Mouse Total
Angiotensinogen Assay Kit (Immuno-Biological Laboratories Co., Gunma,
Japan). Total cholesterol and triglyceride (LabAssay) levels were quantified with
respective kits from Wako Diagnostics (Richmond, VA).
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3.3.4 Assessment of AAAs in AngII-infused mice
A greater than 50% increase in lumen diameter, measured by ultrasound,
was one parameter used to determine AAA incidence. Peri-aortic fat was
carefully collected and placed into RNAlater so that cleaned aortic tissue could
be placed in 10% w/v formalin. Maximal external suprarenal aortic diameters
were obtained from cleaned aortas using NIS Elements imaging software.
Presence and severity of AAA pathology were also graded by two individuals
blinded to the genotype of the mice based on the Type I – Type IV grading
system previously described (64). AAA pathology was only assessed in mice
exhibiting at least 2 signs of successful AngII infusion (defective osmotic pumps
can compromise effective AngII delivery), indicated by low plasma renin
concentrations, increased blood pressure, or visual AAA pathology.
3.3.5 Quantification of atherosclerotic lesion area
After fixation in 10% formalin, aortas were cut longitudinally to expose the
intimal surface and pinned for en face analysis. The arch and thoracic regions
were determined (the arch area encompassed the ascending aorta down to 3
mm below the left subclavian artery; the thoracic area began at this point and
extended 9 mm down the descending thoracic aorta) and lesion areas were
expressed as a percent of the total area for each region. Lesion areas were
calculated using NIS Elements software (Nikon Instruments, Inc., Tokyo, Japan).

99

3.3.6 Quantification of mRNA abundance
RNA was isolated using either Promega Total RNA Isolation System
(Promega, Madison, WI) or Qiagen Lipid RNeasy kit (Qiagen, Valencia, CA).
Reverse transcription reactions were set up with 0.4 µg RNA using qScript cDNA
SuperMix and real-time PCR reactions were performed with PerfeCTa SYBR
Green FastMix using 2 ng of cDNA template (Quanta Biosciences, Gaithersburg,
MD). Standard curves were generated from ten-fold dilutions of concentrated
cDNA from tissues known to express the gene of interest and this standard curve
was used to calculate the starting quantity of template from the given Ct values.
Data are expressed as the ratio of the gene of interest to the starting quantity of
the housekeeping gene 18S.
3.3.7 Determination of adipocyte size
Sections of formalin (10% w/v) fixed pieces of retroperitoneal or
subcutaneous adipose tissue were stained with hematoxylin and eosin (H&E).
Images of slides were obtained at 10x magnification and using the “detect
edges”, image threshold, and object count features of NIS Elements software
(Nikon, Instruments, Inc., Tokyo, Japan), the area of each adipocyte within a 700
x 700 µm measurement frame was quantified. Three measurement frames on
each slide and 3 slides per genotype group were analyzed for morphology.
3.3.8 Lipolysis assay
Epididymal adipose tissue explants (25 mg) were collected from salineinfused AT1aRfl/fl x LDLR-/- and AT1aRaP2 x LDLR-/- mice fed Western diet for a
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total of 5 weeks. Filtered Kreb’s buffer supplemented with fatty-acid free bovine
serum albumin (2% BSA) was used for washes and treatment dilutions. Explants
were washed 3 times and incubated in a 48-well plate containing various
treatments (0.5 mL) for a total of 5 hours, though “conditioned media” was
sampled at 30, 90, and 180 minutes then frozen at -20⁰C. Treatments included
10 µM AngII (Sigma, St. Louis, MO), 1 µM losartan (Merck), 1 µM isoproterenol
(Sigma, St. Louis, MO), or combinations of AngII with losartan or isoproterenol at
these same concentrations (for combination treatments, explants were pretreated in losartan or isoproterenol for 15 minutes prior to addition of AngII). At
the end of the 5-hour incubation, glycerol concentrations were measured from
“conditioned media” (15 µL) using a colorimetric assay (Cayman Chemical Co.,
Ann Arbor, MI). Explants were also collected for protein extraction and
quantification using the Pierce©BCA Assay (Thermo Scientific, Rockford, IL).
Data are expressed as the ratio of glycerol to protein concentrations.
3.3.9 Statistical analyses
Data from the LDLR-/- time course study were analyzed by two way
ANOVA to compare the different diet and duration groups. Student’s t-tests were
used for comparisons between the two genotypes, except in instances where
treatment (saline or AngII infusion) was an additional factor, in which case two
way ANOVA was used to compare the 4 treatment/genotype groups. Post-hoc
analysis of two was ANOVA results used the Holm Sidak test. If normality or
equal variance tests failed, simple transforms were performed or the nonparametric Kruskal-Wallis test was used with Dunn’s post-hoc analysis. Data are
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represented as mean ± SEM and statistical significance was defined as P <
0.05.
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3.4 Results
3.4.1 Diets modulate AT1aR expression in peri-aortic fat
Our first goal was to characterize changes in expression of RAS
components in response to hypercholesterolemia, particularly in peri-aortic fat
(PAF), to better understand how PAF may contribute to AngII-induced vascular
diseases. Chow-fed LDLR-/- mice gained little weight over the 3 month duration
of the study (Figure 3.1A) In contrast, HF- and Western-fed mice exhibited
significant elevations in body weight beginning at 2 and 3 weeks, respectively,
and gained similar amounts of weight (Figure 3.1A). Fat mass increased in mice
fed all diets after 3 months (Figure 3.1B, P < 0.001), though was significantly
increased by Western and HF diets compared to chow (P< 0.001). Importantly,
although Western- and HF-fed mice achieved similar levels of weight gain
(Figure 3.1A), only Western-fed mice exhibited significant hypercholesterolemia
(Figure 3.1C, P < 0.05) and triglyceridemia (Figure 3.1D, P < 0.05).
There were trends for age-dependent downregulation of AT1aR mRNA
abundance in thoracic PAF, while age increased AT1aR mRNA abundance in
abdominal peri-aortic fat of chow-fed mice (Figure 3.2A,B). However, these
effects were not statistically significant. Interestingly, when mice were fed chow
or HF diets, the age-dependent downregulation of AT1aR mRNA abundance in
thoracic PAF was significant. AT1aR mRNA abundance was significantly
decreased by the same extent in thoracic PAF of 2 or 3 month Western or HF
diet-fed mice compared to 1 month (Figure 3.2A). In contrast, AT1aR mRNA
abundance in abdominal PAF was strikingly reduced by both Western and HF
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diets compared to mice fed chow after 3 months of respective diets (Figure
3.2B). Also, Western diet had a more robust effect to increase AT1aR mRNA
abundance in abdominal PAF compared to HF-feeding at 1 and 2 months. In
contrast to AT1aR expression, AGT mRNA abundance in PAF (Figure 3.2C,D)
was not regulated by any of the diets at any time point. In liver, AGT mRNA
abundance was modestly elevated by HF diet at 2 and 3 months, and was
decreased by Western diet at 3 months (Figure 3.2F, P < 0.05).
Plasma renin and AGT concentrations were used as stable and reliable
indicators of systemic RAS activation. Both hypercholesterolemia (65) and HF
diets (100) have been shown to increase circulating angiotensin peptide levels,
indicating an activated RAS. Hypercholesterolemia robustly increased plasma
renin concentrations after 3 months of diet (Figure 3.3A, P < 0.05), while the HF
diet increased circulating AGT levels after 3 months (Figure 3.3B, P < 0.05),
indicating different mechanisms of RAS activation by these diets.
3.4.2 Adipocyte-AT1aR deficiency has no effect on diet-induced
atherosclerosis
To determine the role for endogenous AngII acting at the adipocyte
AT1aR in diet-induced atherosclerosis, AT1aRfl/fl x LDLR-/- and AT1aRaP2 x
LDLR-/- mice were fed Western diet for 3 months beginning at 8 weeks of age.
No differences in body weight, percent fat mass, or percent lean mass were
observed between the two groups (Figure 3.4A,B). Serum cholesterol and
triglyceride levels were also not significantly different between AngII-infused
AT1aRfl/fl and AT1aRaP2 mice (Figure 3.4C,D). Atherosclerotic lesion areas were
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quantified both on the arch and thoracic regions of the aorta. Adipocyte-AT1aR
deficiency had no effect on the development of atherosclerosis in either region of
the aorta (Figure 3.4E,F).
3.4.3 Adipocyte-AT1aR deficiency does not influence AngII-induced AAAs and
atherosclerosis
LDLR-/- mice fed Western diet for 1 week prior to and during subsequent 4
weeks of AngII infusion exhibit increases in atherosclerotic lesion development
and AAA formation. To investigate the effect of adipocyte-AT1aR deficiency on
these AngII-induced pathologies, we infused AT1aRfl/fl x LDLR-/- and AT1aRaP2 x
LDLR-/- mice with AngII for 1 month. Similar to observations in diet-induced
atherosclerosis, there was no effect of adipocyte-AT1aR deficiency on percent
lesion area in either the aortic arch or thoracic regions of AngII-infused mice
(Figure 3.5A,B). Additionally, adipocyte AT1aR deficiency had no effect was on
AngII-induced AAAs, as measured by abdominal aortic lumen and external
diameters (Figure 3.5C,D).
3.4.4 Modest adipocyte hypertrophy is caused by adipocyte-AT1aR deficiency
in retroperitoneal adipose
Adipocyte hypertrophy was observed in lean (LF-fed or AngII-infused
chow fed) AT1aRaP2 mice, so we examined adipocyte morphology of AngII
infused mice fed a Western diet. AngII-infused AT1aRaP2 x LDLR-/- mice did
exhibit adipocyte hypertrophy in retroperitoneal fat (RPF), though the effect was
modest and differences in mean adipocyte size or cell number did not reach
statistical significance (Figure 3.6 A-F). Body weight was not affected by
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adipocyte-AT1aR deficiency in LDLR-/- mice infused with saline or AngII infusion;
however, AngII infusion did reduce body weight and adipose tissue masses to a
greater extent in AT1aRaP2 x LDLR-/- mice compared to AT1aRfl/fl mice (Table
3.2). Adipose tissue lipolysis was examined as a potential mechanism
contributing to adipocyte hypertrophy and increased fat mass, however glycerol
production from adipose explants was unaffected by AngII, losartan, or by
adipocyte-AT1aR deficiency (Figure 3.6G). However, isoproterenol significantly
increase adipocyte lipolysis, which was not influenced by losartan or AngII
(Figure 3.6G).
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3.5 Discussion
AngII is known to promote various vascular pathologies through the
AT1aR in hypercholesterolemic mice, though the cell types mediating these
effects are unknown. We proposed that AngII acts through adipocyte AT1aRs to
promote the development of vascular diseases. Despite investigating models of
both endogenous and exogenously administered AngII, we found no role for the
adipocyte AT1aR in the development of atherosclerosis or AAAs. Interestingly,
adipocyte-AT1aR deficiency did result in modest adipocyte hypertrophy in AngIIinfused mice. These effects were not due to changes in adipose tissue lipolysis
and are possibly due to previously identified reductions of adipocyte
differentiation in mice lacking adipocyte AT1aRs.
The effects of hypercholesterolemia and HF diet on mRNA abundance of
AT1aR in adipose tissue were characterized to understand dietary manipulation
of this receptor as a potential contributor to vascular diseases. In this study,
even though both diets induced weight gain, only LDLR-/- mice fed Western diet
exhibited significant elevations in serum cholesterol and triglyceride levels. The
purpose of using these diets was to determine whether hypercholesterolemia or
high fat feeding was a better stimulus to activate the adipose RAS, however this
study is limited by the inability to distinguish whether differential effects of these
diets were due to the induction of hypercholesterolemia by Western diet, the
different amounts of fat in the diets, or the different sources of dietary fat.
Hypercholesterolemia has been previously reported to upregulate AT1aR
expression in vascular tissues (181-182), though the effects on adipocytes are
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unknown. In mice fed Western diet for 1 month, we also observed an increase in
AT1aR mRNA abundance in abdominal, but not thoracic PAF compared to chowfed controls. However, in contrast to previously observed effects of
hypercholesterolemia to increase vascular wall cell AT1aR expression, in this
study we observed a striking reduction in AT1aR mRNA abundance following 3
months of Western or HF diet feeding in thoracic and abdominal PAF. Effects of
these diets to reduce AT1aR mRNA abundance were more pronounced in
abdominal than thoracic PAF. This may relate to the types of adipocytes in
adipose tissue surrounding these different aortic regions (203). Brown
adipocytes are localized to thoracic PAF, while a mixture of white and brown
adipocytes surround abdominal PAF. Differences in the type of adipocytes in
these different aortic regions may have influenced regulation of AT1aR
expression by Western and/or HF diets. However, since both diets resulted in a
marked reduction in AT1aR mRNA abundance in PAF at 3 months, then
differences in dietary composition or type of adipocytes most likely did not
contribute to diet-induced decreases in AT1aR expression.
Circulating angiotensin peptides are increased in the setting of chronic
Western feeding to LDLR-/- (65) mice as well as in C57BL/6 mice fed a HF diet
for 4 months (100). Results from our study indicate that RAS activation in these
conditions occur through distinct mechanisms. Plasma renin concentrations
were significantly elevated after consumption of the Western diet for 3 months.
These results suggest that increased renin concentrations in plasma most likely
contributed to previously observed elevations in plasma AngII concentrations in
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Western diet-fed LDLR-/- mice (65). However, a well known facet of the RAS in
mice is the existence of negative feedback regulation of renin production in
response to AngII. Thus, it is unclear why elevated plasma AngII concentrations
in LDLR-/- mice fed the Western Diet (65) did not result in negative feedbackmediated reductions in plasma renin concentrations. Indeed, following 1 month
of Western or HF diet-feeding, mice exhibited reductions in plasma renin
concentrations suggestive of increased levels of circulating AngII. Additional
studies, including quantification of plasma AngII concentrations (this was not
performed in this study due to insufficient volumes of mouse plasma) are
required to determine mechanisms for high plasma renin concentrations in 3
month Western diet-fed LDLR-/- mice. However, since whole body AT1aR
deficiency markedly reduces atherosclerosis in LDLR-/- mice (65), then it is
unlikely that these mice exhibit low activity of the systemic RAS. In contrast to
the Western diet, consumption of the HF diet increased plasma AGT levels,
demonstrating an effect of this diet to increase the amount of precursor to
promote the conversion to AngII. Indeed, chronic consumption of this HF diet in
C57BL/6 mice is associated with robust elevations in circulating concentrations of
AngII (100, 258). Although AGT mRNA abundance in adipose tissue was not
regulated by any of the diets, increased fat mass with HF diet along with
increased liver AGT expression are likely contributors to HF-induced elevations
in circulating AngII. In contrast to previous findings (65), we did not observe
elevations in plasma AGT concentrations in Western diet-fed LDLR-/- mice. This
discrepancy is most likely due to different methods for measuring plasma AGT
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(Western blot versus ELISA in our study) or the different controls used (LDLR+/+
vs chow-fed LDLR-/- mice in our study).
Chronic feeding of Western diet to LDLR-/- over a period of 3 months
results in the development of atherosclerotic lesions in the aorta and adipocyteAT1aR deficiency was not protective against lesion formation in this model.
While these findings may be due to the downregulation of AT1aR expression in
PAF surrounding the thoracic region of the aorta observed in the LDLR-/- time
course study, this is unlikely because receptor expression was high through the
first 2 months of diet feeding, which is the time frame during which the initial
phases of lesion formation begin. Evidence for a direct role of adipocytes or
adipocyte-derived factors in the development of atherosclerotic plaques
continues to emerge as more groups characterize the proinflammatory
phenotype of perivascular adipose (51, 109, 188). One approach to studying the
direct influence of adipose tissue in atherosclerosis is the transplantation of nonperivascular fat directly adjacent to the carotid artery in ApoE-/- mice susceptible
to atherosclerosis (188-189). While results from these studies clearly
demonstrate that inflammation in transplanted visceral adipose tissue serves as
a causative factor in lesion formation, it remains unclear whether inflammation of
endogenous perivascular adipose depots is sufficient to contribute to this
disease. Our model of adipocyte-AT1aR deficiency has the advantage of
examining the role of endogenous adipose tissue in vascular diseases.
Adipocyte-AT1aR deficiency, however, did not have an effect on atherosclerosis
in LDLR-/- mice fed Western diet for 3 months, indicating that this receptor has no
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role in adipose tissue inflammation. Other models of adipocyte-specific
deficiency of proatherogenic adipocyte factors are required to delineate the role
of adipocytes in atherosclerosis.
Infusion of AngII for 4 weeks in mice fed Western diet for a total of 5
weeks is a well-established model of AAA formation in LDLR-/- mice (62).
Deficiency of AT1aRs in adipocytes had no effect on the development of AngIIinduced AAAs. Previous work from our lab found that HF diet and the
development of obesity promotes AAA formation in normocholesterolemic
C57BL/6 mice infused with AngII (203). Police, et al. demonstrated increased
MCP-1 secretion from and macrophage infiltration in PAF surrounding the
abdominal region of aorta where AAAs form, leading us to hypothesize that AngII
may be acting at the adipocyte AT1aR to upregulate MCP-1 production, thus
promoting macrophage infiltration and disease progression. Instead of using the
obesity model from the work of Police, et al. (C57Bl/6 mice fed HF diet for 4
months with AngII infusion during the final month of diet), we chose to use a
mouse model of adipocyte-AT1aR deficiency in LDLR-/- mice fed Western diet.
This model allowed us to study the development of both atherosclerosis and
AAAs, and compare our results to previous work investigating cell types involved
in AngII-induced vascular pathologies which have been performed on
hypercholesterolemic LDLR-/- or ApoE-/- mice. The lack of an effect of adipocyteAT1aR deficiency on vascular disease in our model, however, suggests that the
obesity or ApoE-/- models may be more effective in elucidating the role of
adipocyte AT1aRs. While our results demonstrate that 3 months of HF diet
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tended to reduce PAF mRNA abundance of AT1aR and AGT in LDLR-/- mice, this
may not be the case in 4 month HF-fed C57BL/6 infused with AngII for 1 month.
ApoE deficiency presents another potential model to study this receptor because
hypercholesterolemia can be achieved in the absence of Western diet, avoiding
possible diet-induced regulation of adipose RAS components. Future studies
may make use of these models to further examine the role of adipocyte AT1aRs
in the development of atherosclerosis and AAAs.
AngII infusion in several models has been reported to induce weight loss
(34, 37, 77, 202) and our study confirms this in LDLR-/- mice fed Western diet for
5 weeks. Some of these studies suggest that AngII may regulate adipose tissue
lipolysis, however reports are conflicting. To determine if AngII regulates lipolysis
through the adipocyte AT1aR, we measured glycerol production from epididymal
adipose explants from saline-infused AT1aRfl/fl x LDLR-/- and AT1aRaP2 x LDLR-/mice in the presence or absence of AngII, losartan, or the β-adrenergic agonist
isoproterenol. Incubation with AngII, losartan, or a combination of both had no
effect on glycerol production in either genotype, demonstrating that AngII does
not directly regulate lipolysis through the AT1aR. Glycerol production was
dramatically increased when explants were exposed to isoproterenol
independent of AngII co-incubation, suggesting that AngII does not modulate the
lipolytic response to sympathetic stimulation. It is possible that AT1aR activation
by AngII regulates the transcription of genes involved in lipolysis and the 5-hour
incubation of explants throughout the lipolysis assay was insufficient for these
changes to manifest and glycerol production to be affected.
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Adipocyte-AT1aR deficiency was found to reduce adipocyte differentiation
from isolated preadipocytes and cause striking adipocyte hypertrophy in lean but
not obese (Chapter 2). These findings led us to quantify adipocyte size in AngIIinfused mice fed Western diet, revealing modest but not significant adipocyte
hypertrophy in RPF of AT1aRaP2 x LDLR-/- mice. Interestingly, the effect of
adipocyte-AT1aR deficiency to cause adipocyte hypertrophy seems to positively
correlate with the leanness of the mice, with the most dramatic effects observed
LF-fed mice and a lack of effect in obese mice. Obesity and HF-feeding are
associated with inhibited adipocyte differentiation, suggesting that adipocyte
differentiation is partially inhibited in Western fed mice (possibly due to the
shorter study duration or slightly lower fat content of the diet compared to HF)
resulting in modest adipocyte hypertrophy.
Overall the results from these studies confirm that adipocyte-AT1aR
deficiency confers no protection against diet- or AngII-induced vascular diseases,
suggesting that other cell types or synergistic effects between various cell types
are responsible for the effects of AngII through the AT1aR. These studies
confirm previous reports that a diet high in fat limits the regulation of adipocyte
size by adipocyte-AT1aR deficiency.
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Table 3.1 Composition of diets.
Source

Kcal/g
Protein (% of total
kcal)
Carbohydrate (% of
total kcal)
Fat (% of total kcal)
Fat sources

Cholesterol

Standard chow
Harlan Teklad Global
18% Protein Rodent
Diet, 2018
3.1
24

Western
Harlan Teklad
Custom Research
Diet, 88137
4.5
15.2

High Fat
Research Diets, Inc.
D12492

58

42.7

20

18
Soybean oil

42
Milkfat

--

0.2% (0.15% added,
0.5% from milkfat)

60
Lard (91% of fat
kcal), soybean oil
(9% of fat kcal)
0.03%
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5.24
20

Table 3.2 Body and tissue weights in saline or AngII-infused AT1aRfl/fl x
LDLR-/- or AT1aRaP2 x LDLR-/- mice.
Saline
AT1aRfl/fl x
LDLR-/6
33.2 ± 1.6

AT1aRaP2 x
LDLR-/7
30.7 ± 0.9

AngII
AT1aRfl/fl x
LDLR-/19
28.3 ± 0.5*

n
Final body weight
(g)
Liver (g)
1.66 ± 0.18
1.48 ± 0.06
1.41 ± 0.05
Kidney (g)
0.42 ± 0.04
0.37 ± 0.03
0.31 ± 0.01*
Epididymal fat (g)
1.10 ± 0.17
1.14 ± 0.09
0.84 ± 0.07
Retroperitoneal fat
0.40 ± 0.07
0.41 ± 0.04
0.28 ± 0.03*
(g)
Subcutaneous fat
0.61 ± 0.10
0.63 ± 0.06
0.41 ± 0.03*
(g)
BAT (g)
0.16 ± 0.02
0.17 ± 0.02
0.13 ± 0.01
Data are mean ± SEM. *P < 0.05 compared to saline within genotype
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AT1aRaP2 x
LDLR-/24
29.4 ± 0.6
1.46 ± 0.05
0.031 ± 0.01*
1.02 ± 0.06
0.35 ± 0.02
0.50 ± 0.04
0.15 ± 0.01

A

B
% Fat mass
% Lean mass

**
*

100

Weight (g)

40
30

Chow
Western
HFD

20
10

60
40
20

0

0

1

2
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8

Chow West.

9 10 11 12

Weeks on diet

HFD

Chow West.

Baseline

C

HFD
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D
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Chow
Western
HFD

*

1500

*
*
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500

Triglyceride (mg/dL)

2500

Cholesterol (mg/dL)

*, †

*, †

*

80
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1000
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1

2

1

3

2
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Figure 3.1 Characteristics of LDLR-/- mice fed chow, Western, or HF diets for
1-3 months. (A) Body weights through the duration of the study. Compared to
chow-fed mice, body weights of HF- and Western-fed mice were significantly
higher beginning at week 2 (*, P < 0.05) and 3 (**, P < 0.05), respectively. (B) Mice
of all groups had significantly increased % fat mass and reduced % lean mass
after consumption of diets for 3 months (*, P < 0.001 compared to baseline) and
mice fed HF or Western diet had greater fat mass/ reduced lean mass (†, P <
0.001 compared to chow after 3 months). Serum cholesterol (C) and trigycerides
(D) were elevated in Western-fed mice compared to chow at each time point (*, P
< 0.05). Data are represented as mean ± SEM from 6-8 mice/group.
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3

Figure 3.2 mRNA abundance of AT1aR and AGT in peri-aortic fat and liver.
AT1aR mRNA abundance was reduced in thoracic PAF (A) after 2 and 3 months
of Western or HF diet consumption (*, P < 0.05 compared to 1 month within diet)
AT1aR mRNA abundance in abdominal PAF(B) was suppressed in Western- and
HF-fed mice (*, P < 0.05 compared to chow within time group; **, P < 0.05
compared to mice fed Western for 1 month; and ***, P < 0.05 compared to mice
fed Western for 3 months). AGT mRNA abundance in thoracic (C) and
abdominal PAF (D) were unaffected by diet. Liver AT1aR mRNA abundance (E)
was unchanged, however AGT was modestly increased by HF diet and
suppressed after 3 months of Western diet consumption (*, P < 0.05 compared
to chow within month). Data are represented as mean ± SEM from 6-8
mice/group.
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Figure 3.3 Plasma renin and AGT concentrations in LDLR-/- mice fed chow,
Western or HF diets. A, Plasma renin concentrations were suppressed by
chow diet and elevated by Western diet consumption after 3 months (*, P < 0.05
compared to 1 month within diet; **, P < 0.05 compared to chow within month).
B, Plasma angiotensinogen levels were elevated by consumption of HF diets
compared to chow or Western diets (**, P < 0.001) and compared to 1 month of
HF diet consumption (*, P < 0.05). Data are represented as mean ± SEM from 68 mice/group.
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Figure 3.4 Adipocyte-AT1aR deficiency has no effect on diet-induced
atherosclerosis in LDLR-/- mice. A, Body weights of mice fed Western diet for
3 months. B, Percent fat mass was increased and lean mass decreased after 3
months of diet consumption (*, P < 0.05). Serum cholesterol (C) and triglycerides
(D) were unaffected by adipocyte AT1aR deficiency. Lesion areas were
calculated as a percentage of total area in both the aortic arch (E) and thoracic
aorta (F). Data are represented as mean ± SEM from 10-12 mice/group.
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Figure 3.5 Adipocyte-AT1aR deficiency has no effect on the development
of atherosclerosis or AAAs in AngII-infused mice. A, Lesion areas were
calculated as a percentage of total area in both the aortic arch (A) and thoracic
aorta (B). C, Lumen diameters were quantified from ultrasound images taken
prior to, 14 days and 28 days into AngII infusion. D, Maximal external diameters
were measured from aortas cleaned of peri-adventitial tissue.
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Figure 3.6 Adipocyte-AT1aR deficiency causes modest adipocyte
hypertrophy in retroperitoneal fat (RPF) of LDLR-/- mice. Frequency
distributions of adipocyte size in RPF of mice infused with saline (A) or AngII (B).
Representative images of H&E stained RPF from mice infused with saline (C) or
AngII (D). Mean adipocyte size (E) and cell numbers per measurement frame (F)
were unaffected by AngII infusion or adipocyte AT1aR deficiency. G, Production
of glycerol from epididymal adipose explants was used to quantify lipolysis in
response to incubation with AngII, losartan (Los), isoproterenol (Iso), as well as
combinations of AngII with Los or Iso (*, P < 0.001, compared to vehicle).
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SECTION IV: GENERAL DISCUSSION
4.1 Summary
The purpose of the studies described in this dissertation was to test
the hypothesis that AngII regulates adipose tissue development, function, and
inflammation through the adipocyte AT1aR. A mouse model of adipocyte-AT1aR
deficiency was developed using the Cre/LoxP system to investigate these
potential roles of the adipocyte-AT1aR in lean, obese, and hypercholesterolemic
mice. AT1aRaP2 mice fed chow diet for one year exhibited no changes in body
weight or fat mass. To stress these mice, we infused saline or AngII for 28 days,
which led to modest weight loss in AngII infused mice of both genotypes.
However fat mass and glucose tolerance were unchanged. Analysis of adipocyte
morphology revealed modest adipocyte hypertrophy in saline-infused AT1aRaP2
mice. AngII infusion caused a reduction in adipocyte size in AT1aRfl/fl controls,
and, surprisingly, AT1aRaP2 mice were protected from this effect.
Adipocyte-AT1aR deficiency was also studied in mice fed LF or HF diets
for a period of 16 weeks. Lack of AT1aRs had no effect on the body weight, fat
mass, glucose intolerance, or blood pressure on either diet, however all mice fed
HF diet had significant elevations in all of these parameters. Similar to AngIIinfused mice fed chow diet, LF-fed AT1aRaP2 mice displayed striking adipocyte
hypertrophy compared to AT1aRfl/fl mice. This phenotype, however, was lacking
in AT1aRaP2 HF-fed mice.
The adipocyte differentiation capacity of preadipocytes isolated from
AT1aRaP2 mice was reduced, possibly due to downregulation of PPARγ,
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providing a potential mechanism of adipocyte hypertrophy in which the remaining
differentiated adipocytes in AT1aRaP2 mice accrue more lipid over time. The
positive regulation of adipocyte differentiation and PPARγ mRNA abundance by
AngII was also confirmed in 3T3-L1 cells.
The contribution of adipocyte-AT1aRs to vascular disease was also
explored because while AngII is known to promote these diseases through the
AT1aR, the cell type mediating these pathological effects remains unknown.
Adipocyte-AT1aR deficiency in LDLR-/- mice fed Western diet for 3 months had
no effect on the formation of atherosclerotic lesions in the arch or thoracic
regions of the aorta. In a model of AngII-induced AAAs, adipocyte-AT1aR
deficiency also had no effect on atherosclerosis or AAAs. Like LF-fed and AngIIinfused chow-fed AT1aRaP2 mice, adipocyte hypertrophy was also observed in
AT1aRaP2 x LDLR-/- , however the effect was more modest which may relate to
the effects of diets high in fat to suppress adipocyte differentiation. These
changes in adipocyte size and fat mass occurred independent of any changes in
lipolysis.
Overall, the results of these studies suggest that the primary role of the
adipocyte AT1aR is to promote adipocyte differentiation. The in vivo
manifestations of this effect appear to be a regulation of adipocyte size in lean,
but not obese, mice. It is unclear why AT1aRaP2 x LDLR-/- mice fed Western diet
for 5 weeks with AngII infusion display moderate protection from AngII-induced
reductions in fat mass, especially when the effects on adipocyte morphology are
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modest, however future studies including measurements of food intake and
energy expenditure may resolve this matter.
4.2 The interplay between the adipose RAS and metabolic syndrome: Insights
from adipocyte-AT1aR deficiency
4.2.1 Regulation of the adipose RAS in obesity
AngII has been suggested to participate in a feed-forward loop to promote
further AngII production by increasing the expression of AGT in liver (111) and
adipose (154). A study from our group by Lu, et al. demonstrated that chronic
AngII infusion increased mRNA abundance of AGT and AT1R in adipose tissue,
however this regulation was absent in liver (154). Furthermore, increased AGT
expression in adipose was attributed to AT1aR-mediated effects because
losartan reduced increased expression in AT2R deficient mice. Obesity is
associated with RAS activation and high levels of circulating AGT and AngII
levels (100, 268), which may be due in part to increased AGT production by
adipose tissue. It has been unclear, however, whether increased adipose AGT
secretion in obesity is due to the AT1aR-mediated positive feed-forward loop in
adipose tissue described by Lu, et al. To address this possibility, we measured
plasma AGT levels in HF-fed AT1aRfl/fl and AT1aRaP2 mice, and while adipocyteAT1aR deficiency had no effect on plasma AGT concentrations, we did confirm
that circulating AGT levels are increased with HF diet. AGT mRNA abundance
was quantified in liver to determine if liver production of AGT was increased to
compensate for possible reductions in adipose tissue, but liver and adipose AGT
expression were unaffected by adipocyte-AT1aR deficiency. These results
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indicate that AGT production in adipocytes is not regulated by a direct effect of
AngII at adipocyte AT1aR. Increased circulating AGT despite reduced mRNA
abundance in adipose is likely due to the dramatic increases in fat mass with
obesity that result in overall increased levels of adipose-derived AGT.
4.2.2 Contribution of the adipose RAS to metabolic syndrome
Most of the obesity-related disorders associated with the metabolic
syndrome (Table 1.3) were unaffected by adipocyte-AT1aR deficiency, including
high blood pressure, glucose intolerance, and atherogenic dyslipidemias.
Although blood pressure was elevated in mice fed a HF diet or infused with
AngII, adipocyte-AT1aR deficiency did not result in lower blood pressures in
chow, LF, HF, or Western-fed mice. Glucose tolerance was measured in chowfed mice, LF-, and HF-fed mice without any changes in AT1aRaP2 mice compared
to controls. Total cholesterol and triglyceride serum concentrations were not
influenced by adipocyte-AT1aR deficiency in mice fed Western diet for 3 months
or for 5 weeks with concurrent 28-day AngII infusion. Deficiency of adipocyte
AT1aRs also did not impact weight gain in mice chronically fed HF or Western
diets, however unexpected elevations in body weight and fat mass were
observed in AngII-infused mice fed Western diet for 5 weeks. These results
would indicate that adipocyte-AT1aR deficiency has no protective role in the
development of the various elements of metabolic syndrome.
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4.3 Limitations of the model of adipocyte-AT1aR deficiency
4.3.1 Non-specific reductions in AT1aR mRNA abundance
The model of adipocyte-AT1aR deficiency used in these studies was
developed using the Cre/LoxP system, in which the only coding exon of the
AT1aR gene, exon 3, was flanked by LoxP sites and mice were bred to
transgenic mice expressing Cre recombinase driven by the aP2 promoter. The
aP2 protein, also known as fatty-acid binding protein 4 (Fabp4), was originally
described as adipocyte-specific and used by several groups to reduce gene
expression in adipocytes. However, as more of these models have been made,
it has become clear that the aP2 gene is also expressed in other tissues, such as
cardiomyocytes. Indeed, mRNA abundance of AT1aR in AT1aRaP2 mice was
reduced significantly in the heart. To better understand the non-specific
expression of Cre recombinase driven by the aP2 promoter, we bred AT1aRaP2
mice to ROSA26 mice, which contain a stop codon flanked by LoxP sites within
the β-galactosidase gene (241). In tissues where Cre recombinase is expressed,
the stop codon is removed, active β-galactosidase is produced, and activity of
this enzyme can be detected through X-gal staining as a marker of Cre
recombinase expression. Several tissues were collected from AT1aRfl/+,aP2 x
ROSA26+/- (Cre 0/+) mice for X-gal staining and compared to the robust staining
in brown and white adipose depots, staining in heart tissue was present but faint.
Moreover, quantification of heart weight to body weight ratios as a measure of
cardiac hypertrophy, which is AT1aR-mediated (195), revealed no differences
between AT1aRfl/fl and AT1aRaP2 mice (data not shown). Additionally, although
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AngII can have positive chronotropic and inotropic effects (171, 270), there were
no reductions in heart rate (data not shown) or blood pressure in AT1aRaP2 mice.
Therefore, these data suggest that the reductions in heart AT1aR mRNA
abundance were not physiologically relevant.
4.3.2 Model validation
Validating models of cell-specific AT1aR deletion at the protein level is
difficult due to the lack of a specific AT1aR antibody (212). AT1aR mRNA
abundance was quantified in whole adipose tissue lysates, the adipocyte fraction
of collagenase-digested adipose tissue, as well as in adipocytes differentiation
from isolated stromal vascular cells, and residual AT1aR mRNA abundance was
detectable in all of these adipocyte sources from AT1aRaP2 mice. This may
reflect sub-optimal efficiency of Cre recombinase enzyme activity at the LoxP
sites surrounding exon 3 of the AT1aR gene. Another possibility is that AT1aR
deficiency regulates transcription factors controlling aP2 promoter activity. In
adipocytes differentiated ex vivo from AT1aRaP2 mice, aP2 mRNA abundance
was reduced (p = 0.052). If this regulation by AT1aR is at the aP2 promoter,
then it suggests reduced aP2 promoter activity in response to AT1aR deficiency
may subsequently reduce the expression of Cre recombinase, thus
compromising the deletion of AT1aR. The use of another promoter to drive Cre
recombinase activity may be one solution to this issue as well as the issue of
non-specific expression described above. The adiponectin promoter has recently
been suggested to be more efficient and specific than the aP2 promoter for
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adipocyte-specific gene deletion; however studies from our lab using this
promoter also show reductions in target gene expression in heart.
4.4 Insights into regulation of adipocyte size and fat mass by AngII
4.4.1 Differential consequences of adipocyte differentiation in LF- and HF-fed
mice
The finding that adipocyte AT1aR deficiency regulates adipocyte
differentiation and size in vivo could be through several potential mechanisms.
AngII promotes adipocyte differentiation through the adipocyte AT1aR by
upregulating PPARγ expression, which is a major regulator of terminal adipocyte
differentiation from committed preadipocytes (Figure 4.1A). When stromal
vascular cells containing preadipocytes were isolated from subcutaneous
adipose depots of AT1aRfl/fl and AT1aRaP2 mice, preadipocytes from AT1aRaP2
mice had reduced lipid accumulation and mRNA abundance of PPARγ. The in
vivo consequences of reduced adipocyte differentiation are increased lipid
accumulation and hypertrophy of remaining cells (13). Interestingly, this resultant
adipocyte hypertrophy was observed in LF-fed, but not HF-fed, AT1aRaP2 without
any adverse metabolic consequences.
The enhancement of adipocyte differentiation in response to AngII is
arguably a good thing. Research by several groups indicates that formation of
many small adipocytes is less of a health risk than the development of
hypertrophied adipocytes, which can become inflamed and eventually lead to
insulin resistance (248). One potential mechanism linking adipocyte hypertrophy
to inflammation may be an insufficient angiogenic (40) or an increased fibrotic

131

(104) response to hypoxic conditions experienced by adipocytes, leading to cell
death and macrophage infiltration (277). While our finding that mice lacking the
adipocyte AT1aR experience adipocyte hypertrophy is consistent with a reduced
capacity for differentiation, the lack of an inflammatory response to this striking
level of adipocyte hypertrophy is puzzling. Conceivably, the inflammatory
response to adipocyte hypertrophy may be mediated by the actions of AngII
through the AT1aR, in which case deficiency of this receptor would cause
hypertrophy on the one hand, but simultaneously protect from the inflammatory
response. This scenario, however, seems unlikely because it would suggest that
HF-fed AT1aRaP2 mice should be similarly protected from adipose inflammation
and related insulin-resistance, however these mice show no improvements in
glucose or insulin tolerance tests. Alternatively, our data suggests that lean mice
were capable of accommodating larger adipocytes without resulting
inflammation, possibly because the fat pads were still small, such that sufficient
blood flow was maintained to avoid the hypoxic conditions that lead to adipocyte
cell death. Our results indicate that adipocyte hypertrophy alone is insufficient to
drive the development of obesity-related insulin resistance in otherwise lean
mice.
The lack of an effect of adipocyte-AT1aR deficiency on adipocyte size, fat
mass, and body weight in HF-fed was initially surprising. However, further
reading of the literature revealed that adipocyte differentiation may be
suppressed in the setting of obesity (13, 116, 177, 197). Specifically, the ability
of isolated human preadipocytes to successfully differentiate is inversely
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correlated with BMI (116), waist circumference or percent body fat (197), as well
as adipocyte size (referring to the size of adipocytes collected after collagenase
digestion)(101, 116). In fact, some suggest the initiating event in the
development of inflamed adipose tissue is the inhibition of adipogenesis and this
inability to recruit new adipocytes causes the adipocyte hypertrophy that leads to
obesity-related disorders (14, 101). These groups distinguish between
“hyperplastic obesity” (i.e., many small adipocytes) and “hypertrophic obesity”
(fewer but larger adipocytes) in which adipocyte size, not necessarily BMI,
determines the metabolic health of adipose tissue. For instance, one study found
that women with “hyperplastic obesity” have significantly lower plasma insulin
and HOMA-IR levels compared to women with similar BMI characterized as
having “hypertrophic obesity” (13). Conversely, lean individuals with a genetic
predisposition for type 2 diabetes have significantly greater adipocyte size
compared to lean individuals with no predisposition for type 2 diabetes (14). The
mechanism through which adipogenesis is inhibited in obesity appears to be a
defect in the differentiation process and not an inability to recruit stem cells
because the number of precursor cells actually increases with obesity (116, 155).
Inhibited differentiation may be due to an inability to suppress canonical antiadipogenic WNT signaling pathways because incubation with a WNT inhibitor,
DKK1, restores differentiation of preadipocytes from obese individuals to 80%
that of normal weight subjects (101). With all of this in mind, the reason for a lack
of effect of adipocyte-AT1aR deficiency in HF-fed AT1aRaP2 mice may be the
general suppression of adipocyte differentiation already occurring in HF-fed mice.
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These changes in WNT signaling must occur upstream of the effects of AT1aR
on PPARγ in the signaling cascade determining adipocyte differentiation since
adipocyte-AT1aR deficiency did not affect HF-induced downregulation of
differentiation.
4.4.2 Lipolysis
Lipolysis presents another potential mechanism through which AngII may
regulate adipocyte size. Lipolysis is the hydrolysis of triglycerides, the primary
form of lipid storage within adipocytes, into free fatty-acids and glycerol. If AngII
stimulated lipolysis, this mobilization of fatty-acids from adipocytes would limit
adipocyte size and deficiency of adipocyte AT1aRs would have more lipid
accumulation, which is consistent with our findings. However, analysis of
lipolysis from adipose tissue explants determined that AngII did not directly
stimulate lipolysis. If anything, there was a modest increase in basal glycerol
production from AT1aRaP2 explants, which would conflict with the in vivo
adipocyte size quantifications of hypertrophy in these mice. An inhibitory effect
of AngII on lipolysis is consistent with several studies in the literature (31, 96),
including one specifically showing that this effect in adipocytes is AT1R-mediated
(95). However, it is still possible that AngII may participate in long-term
regulation of lipolytic enzymes that neither our lipolysis explants assay nor the
microdialysis with AngII infusion experiments of others are designed to elucidate.
Future work should determine the phosphorylation status and enzyme activity of
hormone-sensitive lipase and adipose triglyceride lipase with a longer duration of
AngII incubation to determine if AngII regulates lipolysis through this mechanism.
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4.5 Future directions
4.5.1 Other mechanisms through which AngII may regulate adipocyte
differentiation and size through the AT1aR
4.5.1.1 Adipocyte aldosterone secretion
It has recently been reported that adipocytes are capable of producing not
only mineralocorticoid-releasing factors (74), but also aldosterone itself (35).
Briones, et al. reported that stimulation of either 3T3-L1 or isolated adipocytes
with AngII increases aldosterone secretion as well as aldosterone synthase
expression (35). Interestingly, this group also found that incubation of 3T3-L1
preadipocytes with a specific inhibitor of aldosterone synthase decreased
adipocyte differentiation significantly (35). Therefore, AngII may stimulate
adipocyte aldosterone production which then acts in an autocrine manner at
adipocyte mineralocorticoid receptors to promote adipocyte differentiation (41).
4.5.1.2 Conversion of white to brown adipocytes
White adipocytes are capable of taking on the phenotypic characteristics
of brown adipocytes, such as increased mitochondrial biogenesis and
thermogenesis, through a process commonly referred to as transdifferentiation
(279). This process is primarily mediated by the actions of PRDM16 to increase
the expression of PGC-1α, UCP-1, Cidea, and other proteins that are hallmarks
of brown adipocytes (233-234) and can be induced by cold exposure (19). The
ability of white adipocytes to transdifferentiate presents an interesting mechanism
through which adipocyte size may be regulated. The accumulation of brown-like
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adipocytes in traditionally white adipose depots would likely mobilize fatty acids
from lipid droplets for oxidation and thermogenesis, reducing lipid accumulation
in white adipocytes. Conversely, reducing transdifferentiation may result in
enlarged adipocytes due to increased lipid accumulation. In our studies, UCP-1
expression was reduced significantly in subcutaneous adipose of AT1aRaP2 mice
fed LF diet (data not shown), and reduced transdifferentiation is consistent with
the adipocyte hypertrophy observed in these mice. However, data collected from
calorimetry chambers during the final week of diet did not reveal any changes in
oxygen consumption (data not shown) nor was body temperature affected by
adipocyte-AT1aR deficiency in any of the models in which it was measured
(chow-fed and Western-fed mice infused with saline/AngII). Nonetheless, other
groups are currently investigating the role of adipocyte AT2Rs in the process of
differentiation and have demonstrated that administration of an AT2R agonist
increases UCP-1 expression in 3T3-L1 adipocytes (data presented at Gordon
Research Conference 2012 by Justin Grobe; as yet unpublished). Further
investigation is required to determine if white adipocyte transdiffferentiation to
brown adipocytes plays a role in the adipocyte hypertrophy and increased fat
mass observed in our models of adipocyte-AT1aR deficiency.
4.5.2 Further exploration of the adipose RAS
4.5.2.1 Overactivation of adipose RAS
An interesting experiment would be to overexpress the AT1aR in
adipocytes and study the effects in vivo. Because the function of adipocyte
AT1aRs has been poorly understood, overexpressing the receptor to
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supraphysiological levels would amplify the effects of AngII and perhaps clarify
what pathways are modulated in adipocytes. Establishing the signaling
pathways and physiological processes affected by AngII would guide future
experiments with adipocyte-AT1aR deficient mice. According to our studies,
AngII promotes adipocyte differentiation through the AT1aR, so overexpression
of this receptor may further increase the number of small adipocytes, though
other outcomes are also possible. These effects may also translate into changes
in fat mass, glucose tolerance, and blood pressure in lean, obese, and
hyperlipidemic mice. Adipocyte-AT1aR deficiency led to increased fat mass in
AngII-infused mice fed Western diet, so overexpression of adipocyte AT1aRs
may result in weight loss in this model. No differences in adipocyte size or
adipose weights were observed in HF-fed AT1aRaP2 mice, possibly due to HF
diet-induced impairment of adipocyte differentiation, but AT1aR overexpression
might restore differentiation in these mice. However, the ability of AT1aR
overexpression to restore adipocyte differentiation in HF-fed mice would depend
on the exact nature of the suppression of differentiation and whether or not
AT1aR signaling can overcome the epigenetic changes brought on by uninhibited
canonical WNT signaling (101).
Studies of adipocyte-AGT overexpression have demonstrated modest
increases in adiposity associated with increased glucose intolerance and adipose
inflammation in lean mice (134, 291). These effects were notably absent in HFfed mice, similar to our findings with adipocyte-AT1aR deficiency (134). Although
the effects of adipocyte-AGT overexpression on adipose tissue were normalized
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by AT2R deficiency in the AGT-overexpression model (291), there may be a role
for enhanced AT1aR activation in AT2R knockout mice and it is also possible
that AT2R deficiency in non-adipocyte cells contributed to these effects.
Overexpression of AT1aRs in adipocytes would clarify whether any of the effects
of AGT overexpression were through direct effects of AngII at the adipocyte
AT1aR, or conversely, adipocyte AGT overexpression could be studied in the
context of adipocyte AT1aR deficiency.
Another method of possibly increasing the activity of the local RAS in
adipose tissue would be to make a mouse model of adipocyte-specific ACE2
deficiency. ACE2 is expressed in adipose tissue and activity of ACE2 in adipose
is blunted after 4 months of HF diet, possibly contributing to the increased
circulating levels of angiotensin peptides observed with HF feeding (100).
Whole-body ACE2 deficiency has been shown to increase atherosclerosis (259).
It might be particularly interesting to observe the effects of adipocyte-ACE2
deficiency in models of vascular disease to see if reductions in adipocyte-ACE2
contribute to the effect observed in whole-body knockouts. Reduced catabolism
of AngII by ACE2 might locally increase AngII levels in perivascular adipose
tissue, enhancing the effects of AngII on adipose tissue macrophages and
nearby vascular wall cells.
4.5.2.2 Exploring the role of adipocyte AT2Rs
In addition to AT1aRs, adipocytes also express AT2Rs. Previous studies
regarding the role of both receptors in the process of adipocyte differentiation
have been mixed and inconclusive (61, 85, 220-221, 225). It would be
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interesting to compare adipocyte deficiency of AT1aRs to that of AT2Rs and
AT1aR/AT2R double knockouts to further delineate the effects that AngII can
have on adipocytes. Complications of these studies include the possibilities that
deficiency of one receptor may change the expression of the other receptors or
enhance AngII signaling through the remaining receptor. AT1aRaP2 mice in our
studies did not show any transcriptional regulation of AT2Rs in response to
AT1aR deficiency in adipocytes; however the possibility of enhanced signaling
remains. The development of mice with adipocyte AT1aR and AT2R deficiency
would help clarify this point.
In AT1aRaP2 mice we observed a reduction in differentiation. If there is
spillover of AngII to enhance AT2R signaling in this mice, there are 3
possibilities: AT2Rs have no effect on differentiation; AT2Rs inhibit
differentiation; or AT2Rs weakly stimulate differentiation but deficiency of
AT1aRs has a more powerful effect to reduce differentiation. AT1aR/AT2RaP2
mice would help distinguish between these possibilities. If the double adipocyte
“knockouts” are phenotypically similar to AT1aRaP2 mice then AT2Rs likely have
no effect. If AngII promotes differentiation through the AT1aR and inhibits it
through the AT2R, then AT1aRaP2 mice would display the greatest reduction in
differentiation and AT1aR/AT2R double “knockouts” would be similar to floxed
controls. Conversely, if AngII promotes differentiation through both receptors,
then AT1aR/AT2R mice would exhibit reduced adipocyte differentiation to a
greater extent than that of AT1aRaP2 mice. While floxed AT2R mice are not
currently available, these would be the most useful tool to understanding the
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possible roles of AT2Rs in adipocytes because the alternative options, using
whole-body AT2R knockout mice or treating AT1aRaP2 mice with a
pharmacologic AT2R antagonist may have indirect effects through other tissues.
4.5.3 Dietary manipulations
In our studies, adipocyte-AT1aR deficiency was studied under several
conditions including aged mice fed chow diet (with or without AngII infusion), lean
mice, obese mice, hypercholesterolemic mice chronically fed Western diet, and
hypercholesterolemic mice fed Western diet for 1 month (with or without AngII
infusion). The most striking effects on adipocyte size was observed in LF-fed
mice and in chow-fed mice infused with AngII (Figure 4.1B), suggesting that the
effects of adipocyte-AT1aR deficiency may be most relevant in lean mice with
high AngII levels and future studies may employ the following models to achieve
these conditions.
4.5.3.1 Low salt diet
To maintain blood pressure under low-salt conditions, increased renin
secretion increases AngII production, which then stimulates aldosterone
secretion to induce sodium and water retention. Feeding AT1aRaP2 mice a low
salt diet represents a unique model where normal weight mice have a
physiologically activated RAS, in contrast to AngII infusion which is an artificial
means of increasing systemic AngII levels and has the added complication of
potential weight loss. A low-salt diet with similar fat content as normal chow may
provide the necessary conditions for the maximum reduction of adipocyte
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differentiation or other effects of adipocyte-AT1aR deficiency, which may then
result in altered adipose tissue function.
A few studies have investigated the effects of high and low salt diets on
adipose tissue. Lima, et al. found that Wistar rats fed a high salt diet for 6 weeks
have increased white adipose tissue mass compared to normal and low salt
groups (83). Interestingly, lipolysis assays performed on an adipocyte
suspension found that basal and isoproterenol-induced lipolysis was stimulated
in rats fed a high salt diet (83). This is consistent with an inhibitory effect of AngII
on lipolysis, because AngII levels are suppressed in high salt conditions so the
inhibition of lipolysis would be curtailed. Interestingly, a human study examining
changes in adipose RAS components with low and high sodium diets found that
expression of AGT, AT1R, and renin in subcutaneous adipose tissue were
unchanged but ACE expression was actually upregulated with a high sodium diet
(75). These results suggest that circulating and tissue RAS components may be
subject to differential regulation by sodium intake and adipose tissue itself can be
directly influenced by sodium status. Experiments using our model of adipocyteAT1aR deficiency would determine if the described changes in white adipose
tissue due to sodium intake are due to direct effects of AngII at the adipocyte
AT1aR.
4.5.3.2 High carbohydrate diet
The LF and HF diets used in our studies are matched for protein content
(20% kcal as protein) and are comprised of varying amounts of the same
ingredients. The HF diet contains roughly 12 times more lard than the LF to
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increase the fat content and consequently, the LF diet contains 3.5 times more
carbohydrates, which makes the LF diet arguably a high carbohydrate diet (70%
kcal from carbohydrates). From our studies, LF diet was the greatest stimulus for
adipocyte hypertrophy in AT1aRaP2 mice, which may suggest a role for adipocyte
AT1aRs in the response of adipose tissue to a high carbohydrate diet and other
high carbohydrate diets may provide interesting models to further elucidate the
roles this receptor. AT1aR mRNA abundance in epididymal adipose tissue of
rats was increased 50% by 14 days of high fructose diet (66% kcal from fructose)
and increased 300% by 3 weeks of a high fructose, high salt diet; however
adipose tissue mass or morphology was not characterized in this study (92).
High sucrose diets also stimulate AT1aR expression specifically in rat epididymal
adipose tissue but not in renal tissue (55). If this drastic upregulation of receptor
expression is in adipocytes and not other cell types, then studying adipocyteAT1aR deficiency under either of these dietary conditions may reveal further
roles of adipocyte AT1aRs.
4.5.3.3 Fasting or caloric restriction
Because the most dramatic effects of adipocyte-AT1aR deficiency on
adipocyte hypertrophy were observed in lean mice, the purpose of adipocyte
AT1aR may be to protect adipocyte differentiation in lean times. Therefore,
adipocyte-AT1aR deficient mice subjected to either acute fasting or chronic
caloric restriction might lose more weight under these conditions compared to
control mice, wherein AngII can temper the loss of adipose mass by promoting
differentiation and/or possibly inhibiting lipolysis. One study examining the
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effects of an overnight fast in AT2R knockout mice found that adipose AT1aR
mRNA abundance doubled in response to fasting (290). Furthermore, AT2R
knockout mice administered valsartan did indeed experience further reductions in
adipocyte size and plasma NEFAs in response to fasting, supporting the idea of
a protective role for AngII/AT1aR signaling in adipose under these conditions
(290). While this study was performed with an acute overnight fast, the
protective role of AngII on adipose tissue may persist in the setting of prolonged
undernutrition, such as caloric restriction. The elevated fat mass observed in our
studies of hyperlipidemic AT1aRaP2 mice infused with AngII suggest that this
theoretical protective role of AngII may be specific to lean mice, and becomes
dysregulated in hypercholesterolemic mice fed Western diet. Alternatively, if
AT1aRaP2 mice exposed to fasting or caloric restriction are also protected from
the resulting reductions in body weight or fat mass, it would suggest that AngII
acts through the adipocyte AT1aR to limit adipose tissue growth in some manner,
though more studies would be required to determine if this is due to the
established pro-differentiation effects of AngII.
4.6 Clinical Implications
The primary role of AngII acting through adipocyte AT1aRs is to promote
adipocyte differentiation, suggesting that AngII would have similar effects in
humans as pharmacologic PPARγ ligands, by increasing the number of small,
healthy adipocytes and potentially increasing insulin sensitivity. This would imply
that treatment with AT1R antagonists would result in adipocyte hypertrophy and
potentially increased fat mass, as observed in AT1aRaP2 mice studied here.
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However, clinical trials to date have found little evidence that ARBs influence
body weight of patients taking them, especially when considering ARBs lacking
PPARγ-agonizing properties that may represent AT1R-dependent effects more
closely, such as losartan or valsartan (113, 132, 164, 236). While two recent
studies have found that losartan may reduce adiposity, measured by ultrasound
(82) or waist circumference (7), the majority of studies have failed to find any
effect of losartan on fat mass. These clinical trials primarily include individuals
with various combinations of metabolic risk factors in their study populations and
thus limit their focus to overweight or obese patients. Our data would suggest
that the lack of an effect of ARB treatment on body weight may relate to the
epigenetic suppression of adipocyte differentiation in the setting of obesity, which
limits the effect of blocking the AT1aR on adipose tissue.
Adipocyte AT1Rs may play a more significant role in lean people,
especially those with an activated RAS. These conditions are met in patients
with chronic heart failure and certain cancers known to have high circulating
levels of AngII and experience weight loss (69). Data from rodent models
confirm that chronic high doses of AngII cause weight loss (34, 37, 47, 68).
Weight loss and cachexia in chronic heart failure patients is associated with a
worse prognosis, which is the basis of the “obesity paradox” whereby obese
patients fare better (66). Indeed, clinical trials indicate that administration of
candesartan (201) or enalapril (10), though not losartan (200), mitigate weight
loss in patients suffering from heart failure. These cachectic effects of AngII have
been attributed to increased sympathetic nervous activity (77) or muscle atrophy
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due to reduced insulin-like growth factor-1 (IGF-1) (34), however, reduced
adiposity is a prominent feature of this phenotype and few have suggested a
direct effect of AngII at adipocyte AT1Rs as a cause of weight loss. Reduced
adiposity may be due to a stimulatory effect of AngII on lipolysis (37, 68),
however other animal studies indicate that AngII has, if anything, an anti-lipolytic
effect on adipocytes (31, 96) and our own data show no effect of AngII on
lipolysis. Alternatively, AngII may not contribute to weight loss through the
adipocyte AT1Rs, but may instead have a compensatory role to protect against
too much weight loss and preserve the adipose depot by stimulating adipocyte
differentiation. In this case, the success of RAS blockade depends on the
magnitude of pro-cachectic effects in some tissues weighed against the anticachectic effects at adipocytes.
4.7 Concluding remarks
Overall these studies suggest the primary role of AT1aRs on adipocytes is
to promote adipocyte differentiation and increase or maintain the number of small
adipocytes. The consequences of AngII acting through adipocyte AT1aRs are
most prominent in lean conditions and are absent in the setting of obesity.
Future studies should identify the mechanisms through which AngII regulates
adipocyte differentiation and explore non-obese models of RAS activation to fully
understand the clinical significance of these findings. Additionally, the impact of
ARB administration on body weight and fat mass in patients suffering from
cachexia should be studied in greater detail.
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Figure 4.1 Role of adipocyte AT1aR in adipocyte differentiation. A, AngII
promotes adipocyte differentiation and the formation of small adipocytes through
adipocyte AT1aRs. B, The effect of adipocyte AT1aR deficiency to promote
adipocyte hypertrophy was greatest in lean mice and there was no effect in
obese mice, which may be due to the amount or source of fat in the diets used
across the various models.
Copyright © Kelly Anne Putnam 2012
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